# 2026年1月7日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 致谢审稿人

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492230)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41492230
**DOI：** 10.1158/1078-0432.CCR-32-1-AR

### 第一部分 原文与翻译

**英文原标题：** Acknowledgment to Reviewers.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本文是一篇编辑性质的致谢声明，旨在对参与《临床癌症研究》期刊同行评审的专家学者表达感谢。文章未涉及实验方法或科学发现，但体现了学术出版对同行评审制度透明性与公正性的重视。虽然缺乏科研内容，但此类文章有助于强化学术共同体的合作精神与质量控制的重要性。

---

## 2. 免疫基因组学在肝细胞癌中的临床应用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492190)
**期刊：** Clinical and molecular hepatology
**PMID：** 41492190
**DOI：** 10.3350/cmh.2025.1323

### 第一部分 原文与翻译

**英文原标题：** Clinical Applications of Immunogenomics in Hepatocellular Carcinoma.

> **英文摘要：**
> Liver cancer is one of the deadliest malignancies, with increasing incidence worldwide. Recent advances in immunotherapy have expanded the options for systemic therapy against advanced hepatocellular carcinoma (HCC), but there are no biomarkers currently available to predict which patients will respond, leading to suboptimal patient selection strategies. Understanding of the genetic and immunologic features of HCC is accelerating rapidly through the use of single cell and spatial transcriptomic techniques. However, there is a need to translate insights gained through these new studies to improve treatment options and improve patient selection. In this review we summarize knowledge of the immunogenomics of HCC, emphasizing recent advances, and discuss progress toward clinical translation.

> **中文摘要：**
> 肝癌是最致命的恶性肿瘤之一，其发病率在全球范围内持续上升。近年来，免疫治疗的进展拓展了晚期肝细胞癌（HCC）系统治疗的可选方案，但目前尚无可用于预测患者应答的生物标志物，导致患者筛选策略不理想。通过采用单细胞和空间转录组技术，对HCC的遗传与免疫特征的认识正在快速推进。然而，如何将这些新研究所得洞见转化为改进治疗选择并优化患者筛选仍是亟待解决的问题。本综述总结了HCC免疫基因组学的相关知识，重点强调最新进展，并探讨其向临床转化的进展。

### 第二部分 AI 大师评价

该综述旨在全面梳理肝细胞癌免疫基因组学的最新进展，强调单细胞与空间转录组技术在揭示肿瘤微环境和免疫特征方面的价值。作者指出，尽管免疫治疗显著拓展了治疗选择，但缺乏预测应答的生物标志物仍是临床瓶颈。文章的创新性在于系统整合基础免疫遗传研究与临床转化路径的观点，指出未来研究应聚焦于生物标志物的应用开发。然而，目前研究主要停留在研究探索阶段，临床验证仍需进一步加强。

---

## 3. RAB25 作为酒精相关性肝病中肝脏特异性内质网应激调节因子的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492189)
**期刊：** Clinical and molecular hepatology
**PMID：** 41492189
**DOI：** 10.3350/cmh.2025.1422

### 第一部分 原文与翻译

**英文原标题：** RAB25 as a Liver-Selective Modulator of Endoplasmic Reticulum Stress in Alcohol-Associated Liver Disease.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究聚焦于RAB25在酒精相关性肝病中的作用，提出其可能作为一种肝脏特异性调节内质网应激的关键分子。虽然文章摘要缺失，但从标题推测，研究可能通过分子与机制层面的分析揭示RAB25在肝细胞稳态和应激反应中的调控作用。该工作在探讨肝病分子靶点方面具有潜在创新性，但具体实验设计与验证结果仍需进一步审查。

---

## 4. 阿昔卡巴基仑细胞注射液联合利妥昔单抗治疗复发难治性大B细胞淋巴瘤：Ⅱ期单臂ZUMA-14研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492094)
**期刊：** Nature cancer
**PMID：** 41492094
**DOI：** 10.1038/s43018-025-01102-1

### 第一部分 原文与翻译

**英文原标题：** Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

> **英文摘要：**
> CD19-negative relapse occurs in ~30% of persons with relapsed or refractory large B cell lymphoma (LBCL) who respond to axicabtagene ciloleucel (axi-cel; CD19-directed chimeric antigen receptor (CAR) T cell therapy). In this phase 2 single-arm study, 26 participants with chemorefractory LBCL received axi-cel in combination with rituximab. The primary endpoint was investigator-assessed complete response rate; select secondary endpoints included duration of response (DOR), axi-cel pharmacokinetics and safety. The complete response rate was 73%. Median DOR was 26.0 months; 46% of participants had an ongoing response at data cutoff. Peak CAR T cell (normalized by tumor burden) and rituximab area-under-the-curve levels were elevated in participants with complete or ongoing response. Axi-cel plus rituximab treatment led to durable responses with no new safety signals despite persistent B cell aplasia and pharmacokinetics of axi-cel were unaffected, indicating that dual targeting of CD19 and CD20 is a feasible and safe approach to potentially limit antigen escape. ClinicalTrials.gov registration: NCT04002401 .

> **中文摘要：**
> 在对阿昔卡巴基仑细胞注射液（axi-cel；一种针对CD19的嵌合抗原受体（CAR）T细胞疗法）有反应的复发或难治性大B细胞淋巴瘤（LBCL）患者中，约有30%会出现CD19阴性的复发。在这项Ⅱ期单臂研究中，26例化疗难治性LBCL受试者接受了阿昔卡巴基仑细胞注射液联合利妥昔单抗治疗。主要终点为研究者评估的完全缓解率；选定的次要终点包括缓解持续时间（DOR）、axi-cel药代动力学及安全性。完全缓解率为73%。中位DOR为26.0个月；在数据截止时，46%的参与者仍保持应答。肿瘤负荷标准化的CAR T细胞峰值水平及利妥昔单抗曲线下面积值在完全或持续应答者中均较高。尽管存在持续的B细胞缺如，但阿昔卡巴基仑细胞注射液联合利妥昔单抗治疗产生了持久的应答，且未发现新的安全性信号，axi-cel的药代动力学未受影响，提示同时靶向CD19和CD20是一种可行且安全的策略，有望减少抗原逃逸。临床试验注册号：NCT04002401。

### 第二部分 AI 大师评价

该研究旨在评估阿昔卡巴基仑细胞注射液联合利妥昔单抗治疗复发难治性大B细胞淋巴瘤的疗效与安全性。研究采用Ⅱ期单臂设计，结果显示较高的完全缓解率和持续应答比例，药代动力学稳定且安全性良好。该策略通过双靶向CD19和CD20，探索了减少抗原逃逸的新途径。创新性在于CAR-T与抗体联合应用，但样本量较小及缺乏对照组限制了结论的普适性。

---

## 5. 孕激素受体激动剂甲地孕酮联合来曲唑用于早期雌激素受体阳性乳腺癌女性的评估：机会窗期、随机、2b期PIONEER试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492093)
**期刊：** Nature cancer
**PMID：** 41492093
**DOI：** 10.1038/s43018-025-01087-x

### 第一部分 原文与翻译

**英文原标题：** Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

> **英文摘要：**
> The use of progestogens in breast cancer has been controversial. Recent preclinical studies have shown that ligand-bound progesterone receptor interacts directly with the estrogen receptor (ER) and reprograms ER transcriptional activity. Progestogen cotreatment enhances the antitumor activity of antiestrogen therapy in mouse xenografts. We report PIONEER, a 198-participant, three-arm, randomized phase 2b window-of-opportunity study for women with early-stage ER breast cancer, which evaluated letrozole with or without megestrol at 40 mg or 160 mg daily. The primary endpoint was the change in tumor proliferation measured by Ki67 immunohistochemistry. Secondary and exploratory endpoints included a comparison of low versus higher dose of megestrol, safety, tolerability and biomarker subgroup analyses. The trial met its primary endpoint, with a greater reduction in proliferation seen when megestrol was added to letrozole. This effect was accompanied by reduced ER genomic binding at canonical binding sites in paired tumor biopsies, indicating reduced ER transcriptional activity. These results support further evaluation of low-dose megestrol, which has two mechanisms for potentially improving breast cancer outcomes in combination with standard antiestrogen therapy: alleviating hot flashes and thereby helping with treatment adherence, as well as a direct antiproliferative effect ( NCT03306472 ).

> **中文摘要：**
> 孕激素在乳腺癌中的应用一直存在争议。近期的临床前研究显示，配体结合的孕激素受体可直接与雌激素受体（ER）相互作用，并重新调控ER的转录活性。孕激素的联合治疗可增强抗雌激素治疗在小鼠异种移植模型中的抗肿瘤活性。我们报告PIONEER研究，这是一项针对早期ER阳性乳腺癌女性的三臂、随机、2b期机会窗期研究，共纳入198名参与者，评估每日40 mg或160 mg甲地孕酮联合或不联合来曲唑的疗效。主要终点为通过Ki67免疫组织化学测定的肿瘤增殖变化。次要及探索性终点包括低剂量与高剂量甲地孕酮的比较、安全性、耐受性及生物标志物亚组分析。试验达到了其主要终点，当甲地孕酮联合来曲唑时，观察到更显著的肿瘤增殖减少。该效应伴随配对肿瘤活检样本中ER在经典结合位点上的基因结合减少，提示ER转录活性下降。这些结果支持进一步研究低剂量甲地孕酮，其与标准抗雌激素治疗联合后可能通过两种机制改善乳腺癌结局：减轻潮热以促进治疗依从性，以及直接的抗增殖作用（NCT03306472）。

### 第二部分 AI 大师评价

本研究旨在探讨甲地孕酮（一种孕激素受体激动剂）联合来曲唑在早期ER阳性乳腺癌患者中的生物学作用与治疗潜力。通过随机、机会窗期2b期试验，作者发现联合用药显著降低了肿瘤增殖指标Ki67，并伴随ER转录活性下降。研究揭示了孕激素与抗雌激素治疗的协同机制，并强调低剂量甲地孕酮的可行性与临床价值。创新性在于分子机制与临床验证的结合，但长期临床结局与安全性仍需进一步证实。

---

## 6. 从胚胎到癌症

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492092)
**期刊：** Nature cancer
**PMID：** 41492092
**DOI：** 10.1038/s43018-025-01098-8

### 第一部分 原文与翻译

**英文原标题：** From embryos to cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该篇文章标题显示其探讨了胚胎发育过程与肿瘤发生机制之间的联系，可能意在揭示细胞增殖、分化及信号通路的共性。虽然摘要缺失，但从主题推测，该研究或综述强调了肿瘤细胞与胚胎细胞在可塑性与微环境互作方面的相似性，提示通过发育生物学视角理解癌症可能开辟新的治疗方向。文章的创新价值体现在跨领域的整合思考上，但缺乏摘要限制了对其研究方法与证据的进一步评估。

---

## 7. 基于人脑干类器官的去 novo H3.3K27M 变异弥漫性中线胶质瘤模型用于解析 GD2 CAR T 细胞功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492091)
**期刊：** Nature cancer
**PMID：** 41492091
**DOI：** 10.1038/s43018-025-01084-0

### 第一部分 原文与翻译

**英文原标题：** De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.

> **英文摘要：**
> Diffuse midline glioma (DMG) is a highly aggressive and untreatable pediatric cancer primarily arising in the pontine brainstem region, necessitating the development of representative models for treatment advance. Here we developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered DMG. We demonstrated that brainstem pontine glial specification is critical for DMG tumorigenesis, yielding infiltrative tumors that recapitulate patient-representative intratumoral heterogeneity. Prolonged GD2 chimeric antigen receptor (CAR) T cell treatment mirrored clinical outcomes and revealed extensive transcriptional heterogeneity, from which both potent effector and dysfunctional CAR T cell populations could be identified. Furthermore, incorporation of myeloid cells generated DMG-specific microglia that reduced treatment efficacy and revealed CAR T cell functional states most vulnerable to microglia-mediated immunosuppression. Thus, we present a representative DMG model offering a months-long experimental window in vitro, which we leveraged to delineate CAR T cell functionality and microglial impact, aiding therapy development for this devastating disease.

> **中文摘要：**
> 弥漫性中线胶质瘤（DMG）是一种高度侵袭性且无法治愈的儿童肿瘤，主要发生于脑桥脑干区域，因此亟需建立具有代表性的模型以推动治疗研究。本文构建了一种由成纤维生长因子4（FGF4）驱动的人脑干类器官模型，并利用该模型在遗传层面上工程化出携带 H3.3K27M 突变的 DMG。研究表明，脑干脑桥胶质谱系的特异性分化对于 DMG 的肿瘤发生至关重要，可产生具有患者代表性的肿瘤内异质性的浸润性肿瘤。长期 GD2 嵌合抗原受体（CAR）T 细胞治疗模拟了临床反应，并揭示了广泛的转录异质性，其中可以识别出具有强效功能和功能失调的 CAR T 细胞群体。此外，加入髓系细胞可生成 DMG 特异性的微胶质细胞，这些细胞降低了治疗效果，并揭示了最易受微胶质细胞介导免疫抑制影响的 CAR T 细胞功能状态。因此，我们提出了一个具有代表性的 DMG 类器官模型，可在体外提供数月的实验窗口，用以解析 CAR T 细胞功能及微胶质影响，为这种毁灭性疾病的治疗开发提供了支撑。

### 第二部分 AI 大师评价

该研究建立了一个以 FGF4 为驱动的人脑干类器官模型，并成功重现 H3.3K27M 变异弥漫性中线胶质瘤的关键生物学特征。通过该模型，作者揭示了脑干胶质分化在 DMG 成瘤中的核心作用，并利用其系统研究了 GD2 CAR T 细胞的抗肿瘤功能及其异质性表现。研究进一步指出，髓系细胞及其生成的微胶质可显著削弱 CAR T 细胞疗效，提示免疫微环境的重要调控作用。该模型为长期体外功能研究及新疗法评估提供了可行平台，但其在完全模拟体内免疫复杂性方面仍存在一定局限。

---

## 8. TGFβ诱导非典型上皮–间质转化以逃避免疫力学监视于肺腺癌休眠转移中。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492090)
**期刊：** Nature cancer
**PMID：** 41492090
**DOI：** 10.1038/s43018-025-01094-y

### 第一部分 原文与翻译

**英文原标题：** TGFβ induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis.

> **英文摘要：**
> Different forms of epithelial-to-mesenchymal transition (EMT) manifest during tumor progression. Little is known about the mechanistic basis and functional role of these distinct EMTs. We explored this question in lung adenocarcinoma (LUAD) primitive progenitors, which are competent to enter dormancy in response to transforming growth factor-β (TGFβ) upon metastatic dissemination. The TGFβ response in these cells includes growth arrest and a full EMT that subsequently transitions into an atypical mesenchymal state of round morphology and lacking actin stress fibers. TGFβ drives this transition by inducing expression of the actin depolymerizing protein gelsolin, which converts a migratory, stress-fiber-rich phenotype into a cortical actin-rich, spheroidal state. This transition lowers the biomechanical stiffness of metastatic progenitors and protects them from killing by cytotoxic lymphocytes. Gelsolin-deficient LUAD progenitors can enter dormancy but succumb to immune surveillance. Thus, quiescent LUAD metastatic progenitors undergo an atypical EMT to avert immune surveillance during TGFβ-driven metastatic dormancy.

> **中文摘要：**
> 在肿瘤进展过程中，上皮–间质转化（EMT）可呈现不同形式。目前对这些不同类型EMT的机制基础和功能作用知之甚少。我们在肺腺癌（LUAD）原始前体细胞中探讨了这一问题，这些细胞在转移扩散后可响应转化生长因子 β（TGFβ）进入休眠状态。TGFβ在这些细胞中的反应包括生长停滞和一次完全的EMT，随后转变为一种呈圆形、缺乏肌动蛋白应力纤维的非典型间质状态。TGFβ通过诱导肌动蛋白去聚合蛋白凝溶胶蛋白（gelsolin）的表达驱动这一转变，从而将一种富含应力纤维的迁移性表型转化为富含皮质肌动蛋白的球状状态。该转变降低了转移前体的生物力学刚度，并保护其免受细胞毒性淋巴细胞的杀伤。缺乏凝溶胶蛋白的LUAD前体虽可进入休眠，但会在免疫监视下被清除。因此，静止状态的LUAD转移前体细胞在TGFβ驱动的转移性休眠过程中经历一种非典型EMT，以逃避免疫监视。

### 第二部分 AI 大师评价

本研究揭示了肺腺癌转移前体在TGFβ信号驱动下通过诱导凝溶胶蛋白表达而发生非典型EMT，从而降低细胞刚度并逃避免疫力学监视。研究结合细胞形态学、分子机制和免疫学特征，明确了TGFβ在转移性休眠维持中的关键作用。其创新点在于提出“非典型EMT”与肿瘤免疫力学逃逸间的功能联系。局限性在于仍需进一步阐明该过程在体内不同微环境中的普适性及其临床干预可行性。

---

## 9. 细胞刚度在转移性休眠期间调控免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492089)
**期刊：** Nature cancer
**PMID：** 41492089
**DOI：** 10.1038/s43018-025-01096-w

### 第一部分 原文与翻译

**英文原标题：** Cell stiffness regulates immune evasion during metastatic dormancy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供参考。

### 第二部分 AI 大师评价

该研究题目表明作者探讨了细胞力学特性——尤其是细胞刚度——在肿瘤转移性休眠期中对免疫逃逸的调控作用，可能揭示癌细胞在休眠状态下存活与免疫系统对抗的关键机制。研究有望结合生物物理学与免疫学手段，解析肿瘤细胞与微环境间的力学信号互作。该方向具有较强创新性，为抗转移疗法提供潜在新靶点；但在‘暂无摘要’条件下，具体实验设计和验证深度仍待明确。

---

## 10. SMARCA5 的缺失将胰腺肿瘤发生过程重新导向再生型细胞命运。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492088)
**期刊：** Nature cancer
**PMID：** 41492088
**DOI：** 10.1038/s43018-025-01066-2

### 第一部分 原文与翻译

**英文原标题：** Loss of SMARCA5 redirects pancreatic tumorigenesis toward a regenerative cell fate.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究题目表明，作者探讨了染色质重塑因子 SMARCA5 在胰腺癌发生中的作用机制，发现其缺失可能改变肿瘤细胞分化方向并诱导再生样表型。这提示胰腺癌的起源细胞可因表观遗传调控的紊乱而发生命运重编程。研究可能采用小鼠模型或多组学策略揭示该途径，对理解胰腺癌可塑性与治疗靶点具有潜在价值。局限性在于具体机制和临床可转化性仍待进一步验证。

---

## 11. 冷冻消融在肝内胆管癌中诱导远隔免疫效应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492087)
**期刊：** Nature cancer
**PMID：** 41492087
**DOI：** 10.1038/s43018-025-01063-5

### 第一部分 原文与翻译

**英文原标题：** Cryoablation induces abscopal immunity in intrahepatic cholangiocarcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究报道冷冻消融可在肝内胆管癌中诱导远隔免疫效应，提示局部物理治疗可能具有全身性免疫调节功能。尽管摘要未公开，但题目暗示研究探索了冷冻消融作为免疫原性细胞死亡诱导策略的潜力。该成果可能为胆管癌的免疫治疗提供新思路，但仍需进一步验证其机制及临床转化可行性。

---

## 12. 可操作转录组：将RNA测序纳入精准肿瘤学的框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492079)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41492079
**DOI：** 10.1038/s41571-025-01110-1

### 第一部分 原文与翻译

**英文原标题：** The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.

> **英文摘要：**
> Comprehensive, multiplexed RNA sequencing (RNA-seq) is increasingly being incorporated into molecular tumour-profiling assays owing to overall cost-effectiveness related to enhanced detection of clinically actionable biomarkers. RNA-seq assays are now quite robust, with turnaround times of a few weeks and reasonable costs that support integration into routine clinical workflows. In this Perspective, we propose a framework for incorporating RNA levels and other RNA-seq data into precision oncology that considers RNA levels of oncogenes, tumour suppressors and diverse therapeutic targets, as well as multigene diagnostic, prognostic and predictive signatures; chimeric gene fusion transcripts; splice variants; RNA-based variant and/or mutation calling; and oncoviral gene expression; among other factors. Additionally, we provide a list of genes representing the current actionable transcriptome focused on the predictive utility of RNA-level overexpression of oncogenes and underexpression of tumour-suppressor genes. This list also includes cell-surface targets, given that RNA profiling has demonstrated that many tumour types have clinically relevant expression levels of such targets. The RNA expression levels of certain genes might also be associated with biological features such as homologous recombination deficiency and DNA mismatch repair defects. Taken together, comprehensive RNA profiling can help to identify additional actionable alterations beyond those detected via DNA sequencing and overcome the challenges faced by conventional low-plex assays (such as immunohistochemistry and in situ hybridization), thereby enhancing therapeutic opportunities for personalized cancer care.

> **中文摘要：**
> 由于对临床可操作性生物标志物的检测能力增强所带来的整体成本效益，综合性、多重化的RNA测序（RNA-seq）正日益被纳入分子肿瘤分型检测中。RNA-seq检测如今已相当成熟，其结果可在数周内完成，成本亦较为合理，从而支持其融入常规临床工作流程。在本观点文章中，我们提出了一个将RNA水平及其他RNA-seq数据纳入精准肿瘤学的框架，该框架考虑了癌基因、肿瘤抑制基因及多种治疗靶点的RNA水平，以及多基因诊断、预后及预测特征；嵌合基因融合转录本；剪接变体；基于RNA的变异及/或突变检测；以及肿瘤相关病毒基因表达等因素。此外，我们还提供了一份代表当前可操作转录组的基因列表，重点关注癌基因RNA水平过度表达及肿瘤抑制基因低表达的预测价值。该列表还包括细胞膜表面靶点，因为RNA分析表明，许多肿瘤类型均在这些靶点上表现出具有临床意义的表达水平。某些基因的RNA表达水平亦可能与同源重组缺陷及DNA错配修复缺陷等生物学特征相关。总体而言，综合RNA分析有助于识别DNA测序未能发现的其他可操作改变，并克服常规低通量检测（如免疫组化和原位杂交）所面临的局限，从而拓展个体化癌症治疗的机会。

### 第二部分 AI 大师评价

本文提出了一个系统性框架，旨在将RNA测序数据纳入精准肿瘤学决策流程。作者不仅关注癌基因和抑癌基因的转录水平，还涵盖了基因融合、剪接变体、RNA突变及病毒基因表达等多种维度。其创新点在于提出“可操作转录组”的概念，并将RNA表达作为临床可预测生物标志物的来源。该框架为RNA测序在临床中的常规化应用奠定了基础，但在标准化流程与临床解释模型的广泛验证方面仍有进一步发展的空间。

---

## 13. 局限性膀胱癌管理的最新进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41492078)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41492078
**DOI：** 10.1038/s41571-025-01104-z

### 第一部分 原文与翻译

**英文原标题：** Advances in the management of localized bladder cancers.

> **英文摘要：**
> Bladder cancer remains a substantial global health burden. Localized, non-metastatic bladder cancer encompasses a spectrum from non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC). Advances in risk stratification, biomarker discovery and therapeutic innovation are reshaping the management of localized bladder cancers. Regarding NMIBC, enhanced cystoscopy techniques, en bloc transurethral resection and a multitude of novel systemic or intravesical treatment strategies, including immunomodulatory, viral, molecularly targeted and/or cytotoxic therapies as well as novel drug delivery mechanisms and chemoablation, are expanding treatment options, particularly for patients with Bacillus Calmette-Guérin-unresponsive disease. For patients with MIBC, refinements in surgical techniques and new neoadjuvant and/or adjuvant systemic therapies, particularly perioperative immunotherapy and potentially antibody-drug conjugates, continue to improve oncological outcomes. Bladder-preserving approaches such as trimodal therapy or even active surveillance following neoadjuvant therapy are also gaining clinical traction, offering selected patients with MIBC an alternative to radical cystectomy. Advances in the identification and application of circulating tumour DNA-based and tumour tissue-based biomarkers will help to further support personalized treatment and follow-up strategies. In this Review, we discuss progress and changes in the management of localized bladder cancer over the past decade and highlight ongoing innovations and future research directions that will shape clinical practice in the coming decade.

> **中文摘要：**
> 膀胱癌仍然是全球重要的健康负担。局限性、非转移性膀胱癌涵盖了从非肌层浸润性膀胱癌（NMIBC）到肌层浸润性膀胱癌（MIBC）的一系列疾病谱。风险分层、生物标志物发现及治疗创新的进展正在重塑局限性膀胱癌的管理方式。对于NMIBC，增强的膀胱镜技术、整块经尿道切除以及多种新型全身或膀胱内治疗策略——包括免疫调节、病毒、分子靶向和/或细胞毒治疗，以及新的药物递送机制和化学消融技术——正在拓展治疗选择，尤其有利于对卡介苗（BCG）治疗无应答的患者。对于MIBC患者，外科技术的改进以及新的新辅助和/或辅助全身治疗，尤其是围手术期免疫治疗和潜在的抗体药物偶联物，正在持续改善肿瘤学预后。保膀胱治疗方案，如三联模式治疗或新辅助治疗后的主动监测，也正获得临床关注，为部分MIBC患者提供了根治性膀胱切除术之外的选择。基于循环肿瘤DNA和肿瘤组织生物标志物的识别与应用进展，将进一步支持个体化的治疗与随访策略。本综述讨论了过去十年来局限性膀胱癌管理的进展与变化，并重点强调了正在进行的创新及未来可能塑造临床实践的研究方向。

### 第二部分 AI 大师评价

本文系统综述了过去十年局限性膀胱癌诊治领域的主要进展，涵盖了非肌层浸润型与肌层浸润型膀胱癌的最新管理思路。作者突出强调风险分层、生物标志物及创新性治疗策略的临床意义，并指出免疫治疗、抗体药物偶联物及基于ctDNA的监测在精准医学中的潜力。文章兼顾技术创新与治疗策略优化，为临床个体化管理提供了前瞻性指导。其局限性在于当前部分新疗法仍需长期随访以验证疗效与安全性。

---

## 14. 用于高通量生成水凝胶微滴中肠类器官的集成微流控平台

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491998)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41491998
**DOI：** 10.1002/advs.202516507

### 第一部分 原文与翻译

**英文原标题：** Integrated Microfluidic Platform for High-Throughput Generation of Intestinal Organoids in Hydrogel Droplets.

> **英文摘要：**
> Organoid research offers valuable insights into human biology and disease, but reproducibility and scalability remain significant challenges, particularly for epithelial organoids. Here, we present an integrated microfluidic platform that addresses these limitations by enabling high-throughput generation of uniform hydrogel microparticles embedded with primary-derived human adult intestinal stem cells. Our platform includes a cell distribution system for homogeneous cell encapsulation and a microfluidic oil-removal module for efficient particle transfer to aqueous media. We demonstrate the successful culture and differentiation of both healthy- and tumor-derived intestinal organoids within these microparticles, achieving high homogeneity and reproducibility. This integrated microfluidic approach holds promise for scalable and standardized organoid production, with potential applications in drug screening, disease modeling, and personalized medicine. encapsulation; high-throughput; hydrogels; microfluidics; organoids.

> **中文摘要：**
> 类器官研究为理解人类生物学和疾病提供了宝贵的见解，但可重复性和可扩展性仍然是重大的挑战，尤其对于上皮类器官而言。本研究提出了一种集成微流控平台，通过实现含原代来源的人肠上皮干细胞的均一水凝胶微粒的高通量生成，以克服这些限制。该平台包含一个用于实现细胞均匀包埋的细胞分配系统，以及一个用于高效将颗粒转移至水相介质的微流控去油模块。我们在这些微粒中成功实现了来源于健康组织和肿瘤组织的肠类器官的培养与分化，获得了高均一性和高可重复性。该集成微流控策略为类器官的规模化和标准化制备提供了新的可能，并在药物筛选、疾病建模和个体化医学等领域具有潜在应用前景。

### 第二部分 AI 大师评价

本研究旨在通过微流控工程解决类器官培养中重现性与产量受限的问题。作者设计了一种集成化平台，实现了人肠上皮干细胞在水凝胶微滴内的高通量均一包裹和后续培养。结果显示该系统能够高效制备健康和肿瘤来源的肠类器官，且具有一致性与可重复性。该方法在药筛、病理建模及个性化医学领域具有较强的创新应用潜力，但未来仍需评估其对不同细胞来源及长期培养效果的适用性。

---

## 15. 器官间串扰：分子机制、生物功能及疾病治疗干预

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491917)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41491917
**DOI：** 10.1038/s41392-025-02329-1

### 第一部分 原文与翻译

**英文原标题：** Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases.

> **英文摘要：**
> Organ cross-talk, also known as the organ axis or organ interaction network, plays a vital role in maintaining physiological homeostasis and responding to environmental stimuli. This review comprehensively integrates cutting-edge observations in organ communication research, with a particular focus on the brain, heart, and gut-the three core organs that garner the most attention in organ connection studies. The current state of organ interaction network research is clearly presented as a Sankey diagram. For brain-related connections, the interactions among the brain-gut, brain-liver, and brain-heart connections are thoroughly reviewed; for heart-related connections, the relationships among the heart-kidney, heart-lung, and heart-liver connections are explored in detail; and for gut-related connections, the interactions among the gut-liver, gut-kidney, and gut-lung connections are emphasized. Additional information on other prevalent organ connections is systematically organized in tables for intuitive presentation. Through the integration of profound insights into molecular mechanisms and biological functions, the complex signaling pathways regulating organ interactions in health and disease states have been systematically elucidated. In terms of therapeutic strategy development, numerous directions with potential application value are proposed on the basis of these research findings. Furthermore, this review meticulously discusses the diverse methods and advanced technologies employed in organ connection research, comprehensively highlighting the critical role of technological support in advancing this field. In the future, this review advocates the adoption of network-driven models, innovative diagnostic approaches, and personalized treatment strategies to offer new perspectives for addressing complex diseases from a systems biology standpoint.

> **中文摘要：**
> 器官间串扰，又称器官轴或器官互作网络，在维持生理稳态和应对环境刺激中起着至关重要的作用。本综述系统整合了器官通信研究的前沿观察结果，特别聚焦于大脑、心脏和肠道——这三个在器官连接研究中最受关注的核心器官。当前器官互作网络的研究现状以桑基图的形式清晰呈现。在与大脑相关的连接方面，系统回顾了脑-肠、脑-肝及脑-心的互作关系；在与心脏相关的连接方面，详细探讨了心-肾、心-肺及心-肝的相互关系；而对于肠道相关的连接，则重点强调了肠-肝、肠-肾及肠-肺的相互作用。关于其他常见器官连接的补充信息则以表格形式系统整理，以便直观展示。通过整合对分子机制与生物功能的深刻洞察，研究系统阐明了健康与疾病状态下调控器官互作的复杂信号通路。在治疗策略的开发方面，本文基于研究成果提出了多种具有潜在应用价值的方向。此外，本综述还详细讨论了用于器官连接研究的多种方法和先进技术，全面凸显了技术支持在推动该领域发展中的关键作用。最后，作者倡导未来应采用基于网络驱动的模型、创新的诊断方法及个体化治疗策略，从系统生物学的视角为应对复杂疾病提供新的思路。

### 第二部分 AI 大师评价

该综述旨在整合器官间相互作用研究的最新进展，系统解析脑—心—肠等关键器官之间的信号网络与生理功能。作者通过图表化展示和结构化总结，揭示了多器官间的复杂沟通机制及其在健康与疾病中的调控作用。文章创新性地将多维度分子机制与潜在治疗策略相结合，强调技术发展在推动该领域研究中的重要性。整体来看，该综述为多器官互作的系统生物学研究提供了全面视角，尽管尚缺乏实验验证和临床转化的具体路径。

---

## 16. 年轻及家族性骨髓增生性肿瘤中常见且具临床相关性的胚系DNA修复基因变异

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491914)
**期刊：** Blood cancer journal
**PMID：** 41491914
**DOI：** 10.1038/s41408-025-01433-3

### 第一部分 原文与翻译

**英文原标题：** Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于年轻及家族性骨髓增生性肿瘤患者中胚系DNA修复基因变异的发生频率及其临床意义。该题目提示作者可能采用基因组测序或多基因检测分析，以探索这些变异在疾病易感性或病程中的作用。此类研究有助于揭示家族性骨髓增生性肿瘤的遗传基础，并为精准诊疗策略提供依据。尽管题目未明确方法与结论，但研究方向具有重要的转化医学价值。

---

## 17. 乳酸：揭示其在人类健康中的不可或缺作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491598)
**期刊：** Molecular cancer
**PMID：** 41491598
**DOI：** 10.1186/s12943-025-02519-z

### 第一部分 原文与翻译

**英文原标题：** Lactate: elucidating its indispensable role in human health.

> **英文摘要：**
> Lactate, traditionally considered just a byproduct of metabolism, is now understood to be a vital regulator in energy metabolism, immune function, and epigenetic changes. Besides serving as an alternative energy source through the "lactate shuttle," it acts as a signaling molecule influencing both normal and abnormal processes in various organs. New research has emphasized its role in lactylation of histones and non-histones, a novel post-translational modification linking metabolic activity with gene expression and immune response. Lactate contributes to immunosuppression, angiogenesis, and the spread of tumors within the tumor microenvironment. Its accumulation is also linked to cardiovascular, metabolic, and neurodegenerative conditions. This shift in metabolism underscores lactate's growing importance in both health and disease, presenting novel therapeutic opportunities, especially in the treatment of cancer and metabolic disorders. This review synthesizes emerging insights into lactate's multifaceted roles and discusses promising therapeutic strategies targeting lactate metabolism, transport, and downstream signaling pathways, with an emphasis on candidates advancing toward clinical translation.

> **中文摘要：**
> 乳酸传统上被认为只是代谢的副产物，但如今被理解为能量代谢、免疫功能以及表观遗传调控中的关键调节因子。除了通过“乳酸穿梭”作为替代能源外，它还作为一种信号分子，影响多个器官中的正常和异常生理过程。最新研究强调了乳酸在组蛋白和非组蛋白乳酰化中的作用，这是一种新型翻译后修饰，将代谢活动与基因表达和免疫反应紧密联系起来。乳酸在肿瘤微环境中促进免疫抑制、血管生成及肿瘤扩散。其积累同样与心血管、代谢及神经退行性疾病相关。这种代谢范式的转变凸显了乳酸在健康与疾病中的重要性，为癌症与代谢性疾病的治疗提供了新的治疗机遇。本综述整合了有关乳酸多重生理功能的最新见解，并讨论了针对乳酸代谢、转运及下游信号通路的潜在治疗策略，重点探讨了已进入临床转化阶段的候选方案。

### 第二部分 AI 大师评价

本文综述深入揭示了乳酸作为代谢调控中心分子的多重角色，从能量代谢到免疫调节与表观遗传修饰均有关键影响。作者系统总结了乳酸在肿瘤微环境及多种疾病中的作用机制，并重点讨论了针对乳酸通路的治疗潜能。文章的创新性在于将乳酰化这一新型修饰机制与疾病进展相联系，为代谢靶向治疗提供了理论依据与临床前方向。但目前乳酸靶向策略的临床验证仍有限，需进一步研究以评估其安全性与疗效。

---

## 18. 整合单细胞与空间分辨转录组学揭示乙型肝炎病毒及华支睾吸虫相关性肝细胞癌的肿瘤间异质性与免疫抑制图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491521)
**期刊：** Molecular cancer
**PMID：** 41491521
**DOI：** 10.1186/s12943-025-02381-z

### 第一部分 原文与翻译

**英文原标题：** Integrating single cell- and spatial- resolved transcriptomics unravels the inter-tumor heterogeneity and immunosuppressive landscape in HBV- and Clonorchis sinensis-associated hepatocellular carcinoma.

> **英文摘要：**
> BACKGROUND: Hepatocellular carcinoma (HCC) is the most common primary liver carcinoma with high lethality. Both of hepatitis B virus (HBV) and Clonorchis sinensis (C. sinensis) are critical infectious contributors to HCC development. However, the inter-tumor heterogeneity and tumor microenvironment (TME) of HCC patients with different infectious background remain largely unknown.
> 
> METHODS: We compiled a cohort of 269 primary HCC patients to assess the clinical impact of C. sinensis and HBV infections on patient prognosis. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomic (ST-seq) analyses were performed on tumor and adjacent normal samples from C. sinensis-associated HCC (CP), and double-infection HCC (DP) patients. Additionally, we integrated publicly available scRNA-seq and ST-seq datasets from HBV-associated (HP) patients. Immunofluorescence, immunohistochemistry and in vitro experiments were conducted to validate inter-tumor heterogeneity among the three HCC subtypes.
> 
> RESULTS: C. sinensis infection is significantly associated with poorer prognosis in HCC patients. Multi-omics analyses revealed distinct inter-tumor heterogeneity in epithelial, immune, and stromal compartments across different HCC subtypes. Tumor cells in the DP group exhibited more malignant marker expression, higher copy number variation scores, increased activation of p53 pathway, and worse survival outcomes. Compared with other HCC subtypes, the TME in DP samples was enriched with SPP1 macrophages, exhausted CD8 T cells and COL1A1 fibroblasts. In contrast, the CP and HP groups showed higher proportions of M2-like macrophages and ENPP2 liver vascular endothelial cells, respectively.
> 
> CONCLUSION: These findings decipher the cellular signatures and their interactions within the TME, shedding light on the inter-tumoral heterogeneity driven by different infections, and the development of targeted therapies for infectious HCC.

> **中文摘要：**
> 背景：肝细胞癌（HCC）是最常见的原发性肝癌，具有极高的致死率。乙型肝炎病毒（HBV）和华支睾吸虫（C. sinensis）均是HCC发生发展的重要感染因素。然而，不同感染背景下HCC患者的肿瘤间异质性及肿瘤微环境（TME）特征仍知之甚少。
> 
> 方法：我们建立了269例原发性HCC患者队列，以评估C. sinensis和HBV感染对患者预后的临床影响。对C. sinensis相关HCC（CP）及双重感染HCC（DP）患者的肿瘤及相邻正常样本进行了单细胞RNA测序（scRNA-seq）和空间转录组测序（ST-seq）分析。此外，整合了来源于HBV相关HCC（HP）患者的公开scRNA-seq和ST-seq数据集。通过免疫荧光、免疫组化及体外实验验证三种HCC亚型间的肿瘤异质性。
> 
> 结果：C. sinensis感染与HCC患者的不良预后显著相关。多组学分析揭示，不同HCC亚型在上皮、免疫及基质成分中呈现明显的肿瘤间异质性。DP组的肿瘤细胞表现出更高的恶性标志物表达、更高的拷贝数变异评分、更强的p53通路激活及更差的生存结局。与其他HCC亚型相比，DP样本的TME富集有SPP1巨噬细胞、耗竭性CD8 T细胞和COL1A1成纤维细胞；而CP和HP组则分别呈现较高比例的M2样巨噬细胞和ENPP2肝血管内皮细胞。
> 
> 结论：这些发现解析了不同TME中细胞特征及其相互作用，阐明了由不同感染驱动的肿瘤间异质性，并为感染相关HCC的靶向治疗发展提供了新思路。

### 第二部分 AI 大师评价

本研究整合单细胞与空间转录组数据，系统解析乙肝病毒与华支睾吸虫相关肝细胞癌的肿瘤间异质性及免疫抑制微环境。研究通过多组学分析揭示不同感染背景下上皮、免疫和基质细胞的显著差异，并发现双重感染HCC具有更恶性的分子特征和更差的预后。该研究在感染性HCC机制与精准治疗潜在靶点方面具有重要创新性，但样本规模及感染因子复杂交互的深层机制仍有待进一步探讨。

---

## 19. EIF4A3/circPTGR1/miR-4725-5p 正反馈环通过 FAK/AKT 信号通路促进结直肠癌进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491503)
**期刊：** Molecular cancer
**PMID：** 41491503
**DOI：** 10.1186/s12943-025-02537-x

### 第一部分 原文与翻译

**英文原标题：** EIF4A3/circPTGR1/miR-4725-5p positive- feedback loop promotes colorectal cancer progression via FAK/AKT signaling pathway.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究题目揭示了EIF4A3、circPTGR1与miR‑4725‑5p形成的正反馈环在结直肠癌进展中的关键作用，并指出其通过FAK/AKT信号通路发挥促进效应。这意味着该分子轴可能在肿瘤细胞迁移与侵袭中起到放大信号的作用。虽然摘要未公开，但从标题可推测研究结合了分子功能验证与信号通路机制探究，具有一定创新性。未来研究可进一步探索该正反馈环的临床应用潜力及其在不同癌种中的普适性。

---

## 20. 炎症性衰老与克隆性造血的相互作用及其对人类疾病的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491423)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41491423
**DOI：** 10.1038/s41580-025-00936-y

### 第一部分 原文与翻译

**英文原标题：** Inflammageing and clonal haematopoiesis interplay and their impact on human disease.

> **英文摘要：**
> Clonal haematopoiesis of indeterminate potential (CHIP) is an ageing-related condition associated with a substantial fraction of circulating leukocytes having descended from a single somatically mutated haematopoietic stem cell (HSC). CHIP increases the risk of haematological malignancies and several chronic diseases (for example, cardiovascular pathologies) and contributes to persistent, low-grade inflammation or inflammageing. Inflammageing, in turn, promotes functional impairment of normal HSCs, including reduced self-renewal potential. By contrast, CHIP-mutant HSCs not only are resistant to inflammageing-induced functional decline but also gain a selective expansion advantage in an inflammatory environment. A recent surge of discoveries has increased our understanding of the CHIP-inflammageing interplay, from a mechanistic and clinical perspective, highlighting its broader relevance to age-related diseases. In this Review, we discuss the molecular and cellular mechanisms that cause CHIP, its interplay with inflammageing, as well as the pathophysiological consequences and the translational implications for diseases that affect older individuals.

> **中文摘要：**
> 不确定潜能的克隆性造血（CHIP）是一种与衰老相关的状态，其特征是相当比例的循环白细胞源自单个发生体细胞突变的造血干细胞（HSC）。CHIP 会增加血液系统恶性肿瘤以及多种慢性疾病（例如心血管疾病）的风险，并促进持续的低度炎症，也称为炎症性衰老（inflammageing）。反过来，炎症性衰老会导致正常造血干细胞的功能受损，包括自我更新能力下降。相比之下，携带 CHIP 突变的造血干细胞不仅对炎症性衰老引起的功能衰退具有抵抗力，还在炎症环境中获得选择性扩增优势。最近出现的大量研究发现，从机制学和临床学角度加深了我们对 CHIP 与炎症性衰老相互作用的理解，突显了其在年龄相关疾病中的广泛意义。在本综述中，我们探讨了导致 CHIP 的分子与细胞机制、其与炎症性衰老的交互作用，以及这种相互作用的病理生理后果及其对老年相关疾病的转化医学意义。

### 第二部分 AI 大师评价

该综述聚焦于克隆性造血与炎症性衰老之间的相互作用，系统阐述了两者在分子与细胞层面的机制以及它们对老年相关疾病的影响。作者总结了 CHIP 如何通过炎症驱动和适应性扩增改变造血系统稳态，从而影响肿瘤及慢性疾病的发生风险。文章的创新之处在于整合了免疫老化、干细胞功能衰退与克隆性演化等领域的最新发现，为理解老年性疾病的共同机制提供了新视角。其局限在于多为综述性分析，仍需更多纵向与功能性实验数据验证推论。

---

## 21. 工程化双特异性外泌体 T 细胞激活剂以靶向免疫检查点抑制剂耐药的转移性黑色素瘤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491256)
**期刊：** Nature biotechnology
**PMID：** 41491256
**DOI：** 10.1038/s41587-025-02890-8

### 第一部分 原文与翻译

**英文原标题：** Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma.

> **英文摘要：**
> Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is often limited by an immunosuppressive tumor microenvironment (TME). Simultaneous targeting of the TME and immune checkpoints is a promising approach to address this limitation. Here we develop an inhalable exosome system that enables co-display of two inhibitory ligands and apply it to treat lung metastases of ICI-resistant melanoma. As immune exclusion in this context is often mediated by Wnt/β-catenin signaling, we harnessed the Alix sorting domain for tandem display of PD-1 and FZD8 to block PD-L1 and Wnt7b, which is overexpressed in ICI-resistant melanoma. This technology, called bispecific exosome activator of T cells (BEAT), enables uniform 1:1 co-display of two proteins on the exosome surface. We show that BEAT concurrently recruits and activates CD8⁺ T cells to reprogram the TME, yielding robust antitumor activity in ICI-resistant melanoma mouse models. Inhaled BEAT outperforms linked dual antibody targeting PD-L1 and Wnt7b in vivo. This approach to tandem protein display may be applicable to diverse ICI-resistant cancers.

> **中文摘要：**
> 使用免疫检查点抑制剂（ICI）的癌症免疫治疗常受到免疫抑制性肿瘤微环境（TME）的限制。同步靶向TME和免疫检查点是一种有前景的方法，可用于克服这一限制。在此，我们开发了一种可吸入的外泌体系统，能够共展示两个抑制性配体，并将其用于治疗对ICI耐药的黑色素瘤肺转移。由于此情境下的免疫排斥常由Wnt/β-连环蛋白信号通路介导，我们利用Alix分选结构域串联展示PD-1和FZD8，以阻断在ICI耐药性黑色素瘤中过度表达的PD-L1和Wnt7b。该技术被称为T细胞双特异性外泌体激活剂（BEAT），可在外泌体表面均匀1:1地共展示两种蛋白。我们表明，BEAT可同时募集并激活CD8⁺ T细胞以重塑TME，从而在ICI耐药性黑色素瘤小鼠模型中产生强大的抗肿瘤活性。吸入式BEAT在体内优于同时靶向PD-L1和Wnt7b的双抗治疗。该串联蛋白展示方法可能适用于多种对ICI耐药的癌症类型。

### 第二部分 AI 大师评价

该研究旨在解决免疫检查点抑制剂治疗黑色素瘤时的免疫耐药问题，创新性地开发了可吸入的双特异性外泌体系统BEAT，实现PD-1与FZD8的精确共展示。通过阻断PD-L1与Wnt7b，BEAT重塑了免疫抑制性肿瘤微环境并显著增强T细胞杀伤效果。动物实验显示，其抗肿瘤效应优于传统双抗策略。此研究在外泌体工程化设计和抗药性肿瘤治疗领域均展现出开创性，但在临床转化及安全性验证方面仍需进一步探索。

---

## 22. 利用 SPLISOSM 从空间转录组学数据中绘制异构体与调控机制图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491254)
**期刊：** Nature biotechnology
**PMID：** 41491254
**DOI：** 10.1038/s41587-025-02965-6

### 第一部分 原文与翻译

**英文原标题：** Mapping isoforms and regulatory mechanisms from spatial transcriptomics data with SPLISOSM.

> **英文摘要：**
> Transcript diversity including splicing and alternative 3' end usage is crucial for cellular identity and adaptation, yet its spatial coordination remains poorly understood. Here we present SPLISOSM (spatial isoform statistical modeling), a method for detecting isoform-resolution patterns from spatial transcriptomics data. SPLISOSM uses multivariate testing with nonparametric kernels to account for spot-level and isoform-level dependencies, achieving high statistical power on sparse data. In the mouse brain, we identify over 1,000 spatially variable transcript diversity events, primarily in synaptic signaling pathways linked to neuropsychiatric disorders, and uncover both known and previously unknown regulatory relationships with region-specific RNA binding proteins. We further show that these patterns are evolutionarily conserved between mouse and human prefrontal cortex. Analysis of human glioblastoma highlights pervasive transcript diversity in antigen presentation and adhesion genes associated with specific microenvironmental conditions. Together, we present a comprehensive spatial splicing analysis in the brain under normal and neoplastic conditions.

> **中文摘要：**
> 包含可变剪接和可变 3' 端使用的转录本多样性对细胞身份与适应性至关重要，但其空间协调机制仍知之甚少。在此，我们提出 SPLISOSM（空间异构体统计建模）方法，用于从空间转录组数据中检测具有异构体分辨率的模式。SPLISOSM 采用结合非参数核的多变量检验，以同时考虑在测点与异构体层面的依赖性，从而在稀疏数据中实现高统计功效。在小鼠脑组织中，我们鉴定出超过 1000 个空间变异的转录本多样性事件，主要集中于与神经精神疾病相关的突触信号通路中，并揭示了与脑区特异性 RNA 结合蛋白之间既有已知亦有新发现的调控关系。进一步地，我们展示这些模式在小鼠与人类前额叶皮层之间具有进化保守性。对人类胶质母细胞瘤的分析显示，在与特定微环境条件相关的抗原呈递及黏附基因中存在广泛的转录本多样性。综上所述，我们在正常及肿瘤状态下的大脑中提供了一项全面的空间剪接分析。

### 第二部分 AI 大师评价

本研究旨在解决空间层面上转录本多样性及其调控机制尚不清晰的问题。作者开发了 SPLISOSM 方法，通过多变量非参数统计提升了从空间转录组数据中检测异构体分辨率模式的能力。研究在小鼠与人脑中揭示了大量与神经精神疾病及肿瘤微环境相关的空间剪接事件，展示了跨物种的保守性。该方法为理解脑区特异性的 RNA 调控网络提供了新工具，但其在复杂组织及临床数据中的计算可扩展性仍需进一步验证。

---

## 23. 利用 CONCORD 揭示单细胞数据集中一致的细胞状态景观

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491253)
**期刊：** Nature biotechnology
**PMID：** 41491253
**DOI：** 10.1038/s41587-025-02950-z

### 第一部分 原文与翻译

**英文原标题：** Revealing a coherent cell-state landscape across single-cell datasets with CONCORD.

> **英文摘要：**
> Revealing the underlying cell-state landscape from single-cell data requires overcoming the critical obstacles of batch integration, denoising and dimensionality reduction. Here we present CONCORD, a unified framework that simultaneously addresses these challenges within a single self-supervised model. At its core, CONCORD implements a probabilistic sampling strategy that corrects batch effects through dataset-aware sampling and enhances biological resolution through hard-negative sampling. Using only a minimalist neural network with a single hidden layer and contrastive learning, CONCORD surpasses state-of-the-art performance without relying on deep architectures, auxiliary losses or external supervision. It seamlessly integrates data across batches, technologies and even species to generate high-resolution cell atlases. The resulting latent representations are denoised and biologically meaningful, capturing gene coexpression programs, revealing detailed lineage trajectories and preserving both local geometric relationships and global topological structures. We demonstrate CONCORD's broad applicability across diverse datasets, establishing it as a general-purpose framework for learning unified, high-fidelity representations of cellular identity and dynamics.

> **中文摘要：**
> 从单细胞数据中揭示潜在的细胞状态景观，需要克服批次整合、去噪和降维等关键障碍。在此，我们提出了 CONCORD，一个在单一自监督模型中同时解决这些挑战的统一框架。其核心机制是一种概率采样策略，通过数据集感知采样校正批次效应，并通过困难负样本采样提高生物学分辨率。CONCORD 仅依赖一个包含单隐藏层的极简神经网络与对比学习，即可在无需深层结构、辅助损失或外部监督的情况下，超越现有最先进方法的性能。它能够跨批次、跨技术甚至跨物种无缝整合数据，从而生成高分辨率的细胞图谱。所得的潜在表示经过去噪并具有生物学意义，能够捕获基因共表达模块、揭示精细的细胞谱系轨迹，并同时保持局部几何关系与全局拓扑结构。我们展示了 CONCORD 在多种数据集中的广泛适用性，确立了其作为学习统一、高保真细胞身份与动态表示的通用框架的地位。

### 第二部分 AI 大师评价

该研究旨在通过 CONCORD 框架统一解决单细胞数据分析中的批次效应、去噪和降维难题。作者以简洁的自监督神经网络结合对比学习，提出概率采样机制以提升生物学分辨率，实现跨技术和跨物种的数据融合。其结果展示了在精简模型结构下依然能够捕获复杂细胞状态关系的强大能力。研究创新性地将数据整合与表征学习融为一体，为构建高精度细胞图谱提供了一种高效、通用的方法。然而，其在极端异构数据或动态系统中的鲁棒性仍需进一步验证。

---

## 24. 靶向丝氨酸合成途径联合紫杉醇与安罗替尼逆转非小细胞肺癌的紫杉醇耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491249)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41491249
**DOI：** 10.1186/s13046-025-03627-w

### 第一部分 原文与翻译

**英文原标题：** Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib.

> **英文摘要：**
> BACKGROUND: Paclitaxel (PTX) serves as a first-line chemotherapeutic agent for the treatment of advanced non-small cell lung cancer (NSCLC). However, the emergence of drug resistance poses a significant threat to patient survival. The serine synthetic pathway (SSP) has been implicated in drug resistance across various cancers and is notably activated in NSCLC. Nevertheless, its role in PTX resistance remains poorly understood.
> 
> METHODS: In this study, we investigated the influence of the SSP on PTX resistance in NSCLC and explored a novel combination therapeutic strategy involving PTX and anlotinib to reverse NSCLC drug resistance. Specifically, using integrated transcriptomic and metabolomic analyses along with in vitro and in vivo experimental approaches, we aimed to elucidate the regulatory role of activated SSP in PTX resistance and to determine whether the combination of anlotinib and PTX can overcome PTX resistance in NSCLC through modulation of the SSP.
> 
> RESULTS: We found that SSP activation drives PTX resistance by promoting the proliferation of PTX-resistant NSCLC cells, increasing the expression and transport function of P-glycoprotein (P-gp), inducing epithelial-to-mesenchymal transition (EMT), and maintaining redox homeostasis. Anlotinib synergizes with PTX by suppressing SSP. This leads to attenuated glycolysis, disruption of the AKT/ERK proliferative signaling pathway, inhibition of P-gp expression and function, reversal of EMT, and redox imbalance, which subsequently elevates reactive oxygen species (ROS) levels and activates the mitochondrial apoptosis pathway, ultimately inducing apoptosis.
> 
> CONCLUSION: Collectively, our study demonstrates that anlotinib combined with PTX, via SSP inhibition, is a promising strategy for overcoming PTX resistance in NSCLC.

> **中文摘要：**
> 背景：紫杉醇（PTX）是治疗晚期非小细胞肺癌（NSCLC）的首选化疗药物。然而，耐药性的出现严重威胁患者生存。丝氨酸合成途径（SSP）已被认为与多种癌症的药物耐受有关，并在NSCLC中明显激活。然而，其在PTX耐药中的作用尚不明确。
> 
> 方法：本研究探讨了SSP对NSCLC中PTX耐药的影响，并研究了一种联合使用PTX与安罗替尼（anlotinib）以逆转NSCLC耐药的新型联合治疗策略。具体而言，我们通过整合转录组学和代谢组学分析，结合体内和体外实验，旨在阐明SSP激活在PTX耐药中的调控作用，并确定安罗替尼与PTX联用是否能够通过调节SSP克服NSCLC的PTX耐药。
> 
> 结果：我们发现，SSP的激活可通过促进PTX耐药性NSCLC细胞的增殖、增加P-糖蛋白（P-gp）的表达与转运功能、诱导上皮-间质转化（EMT）以及维持氧化还原稳态，从而驱动PTX耐药。安罗替尼通过抑制SSP，与PTX产生协同作用。这一过程导致糖酵解减弱、AKT/ERK增殖信号通路受阻、P-gp表达与功能被抑制、EMT逆转以及氧化还原失衡，进而引起活性氧（ROS）水平升高，激活线粒体凋亡通路，最终诱导细胞凋亡。
> 
> 结论：总体而言，本研究表明通过抑制SSP，安罗替尼联合PTX是一种有望克服NSCLC紫杉醇耐药的潜在治疗策略。

### 第二部分 AI 大师评价

该研究针对非小细胞肺癌紫杉醇耐药问题，从代谢重编程角度揭示了丝氨酸合成途径在耐药中的关键作用。作者创新性地提出联合安罗替尼抑制SSP以逆转耐药的策略，并通过多组学和实验验证了其分子机制，包括代谢调控、信号通路干扰和凋亡诱导。结果显示该联合方案能有效削弱癌细胞耐药性，具有显著潜在临床转化价值。研究的优势在于机制阐释全面、验证体系完善，但仍需进一步的临床研究确认安全性与疗效。

---

## 25. 乳腺癌“微生态群落”中的操纵者：巨噬细胞异质性的空间与代谢调控

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491213)
**期刊：** Molecular cancer
**PMID：** 41491213
**DOI：** 10.1186/s12943-025-02551-z

### 第一部分 原文与翻译

**英文原标题：** The puppet master in the breast cancer "microecological community": spatial and metabolic regulation of macrophage heterogeneity.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本研究题目暗示其聚焦于乳腺癌肿瘤微环境中巨噬细胞异质性的空间与代谢调控机制，可能通过揭示巨噬细胞在细胞代谢和定位上的差异，探讨其在肿瘤免疫调节或进展中的关键作用。该研究有望结合空间多组学或代谢组学技术，阐明免疫微环境中“操纵者”角色的动态特征。尽管缺乏摘要细节，但推测其创新点在于从“微生态系统”角度整合空间与代谢调控，为乳腺癌免疫治疗和精准干预提供新的理论依据。

---

## 26. 在强化治疗的急性髓系白血病中，共存的 FLT3 突变在不同分子亚型中的预后影响：来自真实世界基因组数据的洞见

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491155)
**期刊：** Blood cancer journal
**PMID：** 41491155
**DOI：** 10.1038/s41408-025-01438-y

### 第一部分 原文与翻译

**英文原标题：** Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究旨在探讨在接受强化治疗的急性髓系白血病（AML）患者中，不同分子亚型间共存的 FLT3 突变对预后的影响。通过对真实世界基因组数据进行整合分析，作者可能评估了 FLT3 突变的协同或互作效应及其对临床结局的意义。此类研究有助于进一步完善 AML 的分子分层和精准治疗策略，尽管由于缺乏具体结果信息，目前难以评估其方法学创新性与临床推广可行性。

---

## 27. 在门诊微创妇科手术中消除阿片类药物处方：一项随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491106)
**期刊：** Nature medicine
**PMID：** 41491106
**DOI：** 10.1038/s41591-025-04096-6

### 第一部分 原文与翻译

**英文原标题：** Eliminating opioid prescriptions from outpatient minimally invasive gynecologic surgery: a randomized trial.

> **英文摘要：**
> Despite low pain scores after minimally invasive gynecologic surgery (MIGS), opioids remain overprescribed in patients undergoing these procedures. In a single-blind randomized trial conducted at a tertiary-care academic center, we assessed whether a multimodal opioid-free exit prescription (OFP) for analgesia would result in noninferior postoperative pain control compared to an opioid-containing prescription in patients undergoing MIGS. Female patients without prior pain conditions undergoing outpatient laparoscopic MIGS were randomized to receive either an OFP or a restrictive opioid prescription (ROP; five tablets hydromorphone 1 mg) alongside multimodal analgesia. The primary outcome was patient-reported pain on postoperative day (POD) 1. Secondary outcomes included patient-reported pain and measures of recovery such as total opioid consumption, participant mobility, opioid-related side effects, return to emergency room or clinic, need for rescue analgesia prescription, overall satisfaction with pain control and overall satisfaction with postoperative care, which were assessed on POD1 and POD7 by a blinded outcome assessor. Of n = 110 patients randomized, n = 103 completed the study (OFP = 49, ROP = 54). No significant difference in mean pain scores on POD1 (3.1 versus 3.5, P = 0.31) or POD7 (1.0 versus 1.5, P = 0.14) were found. Mobility and satisfaction were comparable. ROP patients experienced more nausea and vomiting (14.3% versus 35.2%, P = 0.01). No OFP patients required rescue opioids. Only 27.8% and 11.1% of ROP patients consumed opioids by POD1 and POD7 respectively. Thus, in patients undergoing outpatient MIGS, an OFP resulted in noninferior postoperative pain compared to an ROP, suggesting that opioids may be safely omitted in this clinical context. ClinicalTrials.gov identifier: NCT04837014 .

> **中文摘要：**
> 尽管在微创妇科手术（MIGS）后疼痛评分较低，但接受这些手术的患者中阿片类药物仍被过度处方。在一家三级学术医疗中心进行的一项单盲随机对照试验中，我们评估了一种多模式无阿片出院处方（OFP）用于镇痛，是否能在术后疼痛控制方面不劣于含阿片处方，针对接受MIGS的患者。无既往疼痛病史的女性门诊腹腔镜MIGS患者被随机分为两组：接受OFP或限制性阿片处方（ROP；5片1 mg氢吗啡酮），两组均配合多模式镇痛。主要结局为术后第1天（POD1）患者自报的疼痛评分。次要结局包括患者自报的疼痛及恢复指标，如总阿片消耗、患者活动能力、阿片相关副作用、急诊或门诊复诊情况、是否需要额外处方镇痛药、对疼痛控制的总体满意度以及对术后护理的总体满意度，这些指标均由盲法评估者在POD1和POD7进行评估。共有110名患者被随机分配，其中103人完成研究（OFP = 49人，ROP = 54人）。POD1（3.1 vs 3.5，P = 0.31）和POD7（1.0 vs 1.5，P = 0.14）的平均疼痛评分无显著差异。两组的活动能力和满意度相当。ROP组患者出现更多恶心和呕吐（14.3% vs 35.2%，P = 0.01）。OFP组无患者需要追加阿片镇痛。仅有27.8%与11.1%的ROP组患者分别在POD1与POD7使用了阿片类药物。因此，对于接受门诊MIGS的患者，OFP在术后疼痛控制上不劣于ROP，提示在该临床情境下可安全省略阿片类药物。临床试验注册号：NCT04837014。

### 第二部分 AI 大师评价

本研究旨在验证门诊微创妇科手术中完全去除阿片类药物出院处方是否可行。研究采用单盲随机对照设计，比较无阿片出院方案与限制性阿片处方在术后疼痛控制与患者恢复方面的差异。结果显示两组疼痛评分、活动力及满意度相当，而含阿片组出现更多恶心呕吐等不良反应。该研究创新性地提出无阿片镇痛可在特定术式中安全实施，为临床阿片减量提供了高质量证据，但样本量和单中心设计可能限制结果的普适性。

---

## 28. 多癌种筛查的伦理问题

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491105)
**期刊：** Nature medicine
**PMID：** 41491105
**DOI：** 10.1038/s41591-025-04111-w

### 第一部分 原文与翻译

**英文原标题：** The ethics of multi-cancer screening.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文章发表于《Nature Medicine》，聚焦于多癌种筛查这一近年来快速发展的领域所引发的伦理学议题。虽然未提供摘要，但从标题可推测，作者可能探讨了多癌筛查技术在早期发现与过度诊断、知情同意、资源分配等方面的伦理平衡。此类研究对于制定公共卫生政策与临床指南具有重要参考价值，有助于在技术进步与伦理责任之间建立适当的界限。

---

## 29. 立即减少临床试验中的官僚作风

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491100)
**期刊：** Nature medicine
**PMID：** 41491100
**DOI：** 10.1038/s41591-025-04055-1

### 第一部分 原文与翻译

**英文原标题：** Reduce bureaucracy in clinical trials now.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文题强调应立即采取行动减少临床试验过程中的繁琐行政和监管程序，以加速医学创新和患者获益。尽管全文未提供摘要，但从标题可推测作者旨在呼吁改革现有临床研究体系，简化审批与管理流程。文章可能在健康政策或科研管理领域具有强烈的现实导向与启示性。其局限在于缺乏具体的实证或实施细节。

---

## 30. 基于人工智能的虚拟空间蛋白质组学：从组织病理学图像中实现肺癌可解释生物标志物发现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41491099)
**期刊：** Nature medicine
**PMID：** 41491099
**DOI：** 10.1038/s41591-025-04060-4

### 第一部分 原文与翻译

**英文原标题：** AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.

> **英文摘要：**
> Spatial proteomics enables high-resolution mapping of protein expression and can transform our understanding of biology and disease. However, major challenges remain for clinical translation, including cost, complexity and scalability. Here we present H&E to protein expression (HEX), an AI model designed to computationally generate spatial proteomics profiles from standard histopathology slides. Trained and validated on 819,000 histopathology image tiles with matched protein expression from 382 tumor samples, HEX accurately predicts the expression of 40 biomarkers encompassing immune, structural and functional programs. HEX demonstrates substantial performance gains over alternative methods for protein expression prediction from H&E images. We develop a multimodal data integration approach that combines the original H&E image and AI-derived virtual spatial proteomics to enhance outcome prediction. Applied to six independent non-small-cell lung cancer cohorts totaling 2,298 patients, HEX-enabled multimodal integration improved prognostic accuracy by 22% and immunotherapy response prediction by 24-39% compared with conventional clinicopathological and molecular biomarkers. Biological interpretation revealed spatially organized tumor-immune niches predictive of therapeutic response, including the co-localization of T helper cells and cytotoxic T cells in responders, and immunosuppressive tumor-associated macrophage and neutrophil aggregates in non-responders. HEX provides a low-cost and scalable approach to study spatial biology and enables the discovery and clinical translation of interpretable biomarkers for precision medicine.

> **中文摘要：**
> 空间蛋白质组学能够实现蛋白表达的高分辨率绘图，并可显著改变我们对生物学和疾病的理解。然而，其临床转化仍面临主要挑战，包括成本、复杂性和可扩展性问题。在此，我们提出了一种从常规组织病理切片计算生成空间蛋白质组学图谱的人工智能模型——H&E 到蛋白表达（HEX）。HEX 在来自 382 个肿瘤样本的 819,000 个匹配蛋白表达的组织病理图像块上进行了训练和验证，能够精准预测涵盖免疫、结构和功能程序的 40 个生物标志物的表达。与其他基于 H&E 图像预测蛋白表达的方法相比，HEX 展现出显著的性能提升。我们还构建了一种多模态数据整合方法，将原始 H&E 图像与 AI 生成的虚拟空间蛋白质组学相结合，以增强预后预测能力。将其应用于 6 个独立的非小细胞肺癌队列（共 2,298 名患者）中，HEX 支持的多模态整合使预后准确性提高了 22%，免疫治疗反应预测提升了 24–39%，相较于传统的临床病理和分子生物标志物表现更优。生物学解释揭示了空间上组织的肿瘤–免疫生态位可预测治疗反应，其中应答者中观察到辅助性 T 细胞与细胞毒性 T 细胞的共定位，而非应答者中则出现免疫抑制性的肿瘤相关巨噬细胞和中性粒细胞聚集。HEX 提供了一种低成本且可扩展的研究空间生物学手段，为精准医学中可解释性生物标志物的发现与临床转化奠定了基础。

### 第二部分 AI 大师评价

本研究旨在利用人工智能方法，从常规 H&E 组织病理图像计算生成虚拟空间蛋白质组学图谱，以实现肺癌中可解释生物标志物的发现。研究构建了 HEX 模型，并在大规模样本上完成训练和验证，准确预测多种关键蛋白标志物的空间表达。通过多模态整合，HEX 在提升预后和免疫治疗反应预测方面显著优于传统方法。其创新在于大幅降低空间蛋白质组学的技术与经济门槛，促进空间生物信息在临床转化中的应用；但仍需在多中心验证和跨癌种推广方面进一步探索其普适性。

---

## 31. 三阴性原发性骨髓纤维化：表型、基因型及预后比较分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490969)
**期刊：** Blood cancer journal
**PMID：** 41490969
**DOI：** 10.1038/s41408-025-01440-4

### 第一部分 原文与翻译

**英文原标题：** Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于原发性骨髓纤维化（PMF）中罕见的“三阴性”类型，即缺乏常见驱动突变（如JAK2、CALR、MPL）的患者群体。通过系统比较表型、基因型及临床结局，研究旨在揭示其独特的分子特征和预后差异。该分析可能有助于完善PMF的风险分层体系并指导个体化治疗，但由于样本量有限及分子谱复杂，仍需进一步研究验证。

---

## 32. ERK2介导的EIF4B Ser93位点磷酸化通过促进上皮-间质转化驱动结直肠癌转移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490890)
**期刊：** Cell death & disease
**PMID：** 41490890
**DOI：** 10.1038/s41419-025-08375-5

### 第一部分 原文与翻译

**英文原标题：** EIF4B Ser93 phosphorylation by ERK2 promotes epithelial-mesenchymal transition to drive colorectal cancer metastasis.

> **英文摘要：**
> Colorectal cancer (CRC) is the third most common malignant tumor and the second leading cause of cancer-related mortality globally. Epithelial to mesenchymal transition (EMT) contributes to CRC metastasis and poor prognosis. Aberrant protein phosphorylation is implicated in CRC progression, warranting further investigation into its molecular mechanisms. Herein, we have identified significant alterations in protein phosphorylation associated with CRC through tandem mass tag (TMT) label-based phosphoproteomic analysis. The functions and enriched signaling pathways of these proteins were predominantly linked to the EMT process. Notably, the phosphorylation of eIF4B at Ser93 exhibited the most pronounced increase in CRC, a finding that was further validated in CRC tissues and cell lines by a newly generated antibody targeting eIF4B Ser93 phosphorylation. Phosphorylation of eIF4B Ser93 promoted CRC progression and metastasis both in vitro and in vivo. Mechanistically, eIF4B Ser93 phosphorylation decreased ubiquitination-mediated eIF4B degradation and enhanced its translation activity, through which it facilitated the translation of mesenchymal markers. Additionally, ERK2 directly phosphorylated eIF4B at Ser93, while inhibiting this phosphorylation is essential for the anti-cancer efficacy of the ERK2 inhibitor, Vx-11e. Together, the phosphorylation of eIF4B Ser93 driven by ERK2 promotes CRC growth and metastasis through the activation of EMT. Our findings indicate a novel therapeutic target and provide promising strategies for clinical intervention in human CRC.

> **中文摘要：**
> 结直肠癌（CRC）是全球第三大常见恶性肿瘤，也是癌症相关死亡的第二大原因。上皮-间质转化（EMT）促进了CRC的转移及不良预后。异常的蛋白磷酸化与CRC进展密切相关，亟需进一步阐明其分子机制。在本研究中，我们通过基于串联质谱标签（TMT）的磷酸化蛋白组学分析，鉴定出了与CRC相关的显著蛋白磷酸化变化。这些蛋白的功能及富集信号通路主要与EMT过程相关。值得注意的是，eIF4B在Ser93位点的磷酸化在CRC中表现出最显著的升高，此发现通过新制备的针对eIF4B Ser93磷酸化的抗体在CRC组织及细胞系中得到了进一步验证。eIF4B Ser93磷酸化在体内外均促进了CRC的进展和转移。从机制上看，eIF4B Ser93的磷酸化减少了其经泛素化介导的降解并增强了其翻译活性，从而促进了间质标志物的翻译。此外，ERK2可直接在Ser93位点磷酸化eIF4B，而抑制此磷酸化对于ERK2抑制剂Vx-11e的抗癌作用至关重要。总体而言，ERK2驱动的eIF4B Ser93磷酸化通过激活EMT促进了CRC的生长与转移。我们的研究揭示了一个新的治疗靶点，并为人类CRC的临床干预提供了有前景的策略。

### 第二部分 AI 大师评价

本研究针对结直肠癌进展中的关键分子机制展开，利用磷酸化蛋白组学系统筛查发现eIF4B Ser93位点在癌症中高度磷酸化，且受ERK2直接调控。研究从分子到细胞及动物模型多层次验证了其在促进EMT及转移中的功能。机制上揭示磷酸化可稳定eIF4B并增强其翻译活性，为ERK-MAPK信号轴与蛋白翻译调控间的关联提供了新见解。该研究提出了eIF4B Ser93磷酸化作为潜在治疗靶点的可能性，但其临床可转化性仍需进一步验证。

---

## 33. 宫颈鳞状癌同步放化疗前的新辅助免疫检查点抑制治疗（GINECO“机遇窗口”COLIBRI研究）：一项II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490885)
**期刊：** Nature communications
**PMID：** 41490885
**DOI：** 10.1038/s41467-025-67646-z

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

> **英文摘要：**
> Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab. We show, using multiplex-immunofluorescence tissue imaging, a significantly increased CD8/FOXP3 cell ratio (primary endpoint; increase of 0.87 cells/mm², P = 0.0164) and proliferative CD8 T-cell density after one cycle of combination immunotherapy. HOT score (27-gene-based signature identifying immunologically active tumors) also increased significantly (exploratory analysis; 0.17, P < 0.0001). Objective response rates (secondary endpoint) were 13% immediately after combination immunotherapy, 98% (65% complete response) after chemoradiation, and 90% at treatment completion. High HOT score at baseline and immune changes induced by combination immunotherapy were associated with complete response at treatment completion. Induction immunotherapy may prime tumors for improved response to standard therapy.

> **中文摘要：**
> 将免疫治疗与放化疗相结合对于局部晚期宫颈癌具有良好疗效。然而，诱导性联合免疫治疗对免疫调节和治疗反应的影响尚不清楚。在本II期临床试验（NCT04256213）中，40名局部晚期宫颈癌女性患者在接受标准放化疗之前，先接受一周期尼伏单抗联合易普利单抗的免疫治疗，随后进行尼伏单抗维持治疗。通过多重免疫荧光组织成像，我们发现接受一周期联合免疫治疗后，CD8/FOXP3细胞比值显著升高（主要终点；增加0.87个细胞/mm²，P=0.0164），并且增殖性CD8 T细胞密度增加。HOT评分（基于27个基因的免疫活性肿瘤特征签名）也显著升高（探索性分析；0.17，P<0.0001）。客观缓解率（次要终点）在联合免疫治疗后立即为13%，放化疗后为98%（其中65%完全缓解），治疗结束时为90%。基线时HOT评分较高以及联合免疫治疗诱导的免疫变化与治疗结束时的完全缓解有关。诱导性免疫治疗可能通过“预激活”肿瘤，从而改善其对标准治疗的反应。

### 第二部分 AI 大师评价

本研究是一项探索新辅助免疫检查点阻断在宫颈鳞状癌同步放化疗前应用的II期临床试验，旨在评估其对免疫微环境和治疗反应的影响。结果显示，尼伏单抗加易普利单抗诱导治疗可显著提升肿瘤内CD8/FOXP3比例及HOT评分，并与后续放化疗的完全缓解率相关。该研究首次在人群中提供了免疫预处理可“预热”肿瘤以增强标准放化疗效应的证据。尽管样本量有限且为单臂研究，其结果为宫颈癌免疫-放化疗一体化策略提供了重要临床依据与生物学线索。

---

## 34. EZH2抑制剂通过协同调控YAP及促凋亡因子增强乳腺癌对HER2激酶抑制剂的敏感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490884)
**期刊：** Cancer research
**PMID：** 41490884
**DOI：** 10.1158/0008-5472.CAN-24-3113

### 第一部分 原文与翻译

**英文原标题：** EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Pro-apoptotic Regulators.

> **英文摘要：**
> Human epidermal growth factor receptor 2 positive (HER2+) tumors account for 20% of breast cancers. While a variety of HER2-targeted therapies have been developed, tumors can exhibit de novo or acquired resistance, and metastatic disease remains incurable. Here, we showed that EZH2 inhibitors shift the epigenetic state of HER2+ tumors, dramatically enhancing baseline responses to HER2 kinase inhibitors and re-sensitizing drug-resistant tumors in vitro and in vivo. Specifically, EZH2 silenced the pro-apoptotic gene BMF by catalyzing H3K27 trimethylation (H3K27me3) at regulatory sequences. EZH2 inhibitors promoted the loss of H3K27me3, but this stimulated the binding of repressive YAP/TEAD complexes at the BMF locus, which still restricted expression. However, in the presence of EZH2 inhibitors, HER2 kinase inhibitors triggered the dissociation of repressive YAP/TEAD complexes, potently upregulated BMF, and killed resistant cells. Accordingly, EZH2 inhibitors cooperated with genetic or pharmacological inhibition of YAP/TEAD, which similarly induced BMF expression and apoptosis. Together, these findings show how EZH2 and YAP/TEAD coordinately insulate the BMF locus and demonstrate that EZH2 inhibitors can be used to reprogram HER2+ tumors, resulting in a dramatic sensitization to HER2 kinase inhibitors and enhanced killing of residual disease.

> **中文摘要：**
> 人表皮生长因子受体2阳性（HER2+）肿瘤约占乳腺癌的20%。尽管已开发出多种针对HER2的治疗手段，但肿瘤可能表现出原发性或获得性耐药性，且转移性疾病仍然无法治愈。本研究显示，EZH2抑制剂可改变HER2+肿瘤的表观遗传状态，显著增强其对HER2激酶抑制剂的基础反应，并在体内外重新使耐药肿瘤恢复敏感。具体而言，EZH2通过在调控序列上催化H3K27三甲基化（H3K27me3）以沉默促凋亡基因BMF。EZH2抑制剂可促进H3K27me3的去除，但这同时促进了抑制性YAP/TEAD复合物在BMF位点的结合，从而仍限制其表达。然而，在EZH2抑制剂存在的情况下，HER2激酶抑制剂可诱导抑制性YAP/TEAD复合物的解离，强烈上调BMF表达并杀死耐药细胞。因此，EZH2抑制剂与基因或药物抑制YAP/TEAD的方式具有协同效应，同样可诱导BMF表达及细胞凋亡。综上所述，这些发现揭示了EZH2与YAP/TEAD如何协同调控BMF基因位点，并表明EZH2抑制剂可用于重新编程HER2+肿瘤，从而显著增强其对HER2激酶抑制剂的敏感性并提高对残余病灶的杀伤效应。

### 第二部分 AI 大师评价

该研究旨在探讨EZH2抑制剂如何通过表观遗传重塑增强HER2阳性乳腺癌对HER2激酶抑制剂的反应性。作者揭示了EZH2抑制BMF基因表达的机制，并发现其与YAP/TEAD复合物的交互共同调控肿瘤细胞凋亡路径。实验结果显示，EZH2抑制剂不仅恢复耐药细胞的敏感性，还与YAP/TEAD抑制产生协同促凋亡作用。该研究创新性地揭示了表观遗传调控与信号通路共同作用的机制，为耐药HER2+乳腺癌的联合治疗提供了新的策略。

---

## 35. 肝癌的“热点区域”：代谢分区、铁死亡与肝细胞癌的起源

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490712)
**期刊：** Cancer research
**PMID：** 41490712
**DOI：** 10.1158/0008-5472.CAN-25-5839

### 第一部分 原文与翻译

**英文原标题：** Hot zones for liver cancer: metabolic zonation, ferroptosis, and the origins of HCC.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is a major cause of cancer-related death and is often resistant to treatment, partly because it develops after decades of chronic injury in a metabolically heterogeneous organ. Anatomically, the liver is organized into lobules with three concentric zones, each with distinct gene expression and metabolic programs, but whether cancer favors any particular zone has remained unclear. In a new study, Guo and colleagues use sophisticated mouse genetics to introduce cancer-driving mutations in specific liver zones. By combining this with spatial transcriptomics, they track premalignant hepatocytes within the tissue microenvironment. They discover that periportal zone-1 clones expand and persist more than the rare, relatively less fit clones in pericentral zone-3. Paradoxically, however, HCC mainly arises from zone-3 hepatocytes across multiple oncogenic models, revealing a striking disconnect between clonal expansion and tumorigenic potential. A functional screen of transcripts enriched in zone-3 identifies the glutathione S-transferases Gstm2 and Gstm3 as key factors in transformation. These enzymes maintain redox balance and suppress ferroptosis in early mutant cells. Genetic deletion, hepatocyte-specific knockdown, and irreversible chemical inhibition of GSTMs all increase oxidative stress and ferroptosis, preventing tumor formation. Ectopic expression of Gstm3 in zone-1 is sufficient to reprogram these cells into a cell-of-origin compartment. These findings define the 'tumorigenic zonation" of the liver and suggest that targeting ferroptosis vulnerability could be a promising therapeutic strategy for HCC.

> **中文摘要：**
> 肝细胞癌（HCC）是癌症相关死亡的主要原因之一，且常对治疗具有耐受性，部分原因在于它是在代谢异质性器官中经历数十年慢性损伤后发展而成。从解剖学上看，肝脏由具有三层同心区域的肝小叶组成，每个区域具有独特的基因表达和代谢程序，但癌症是否偏好特定区域仍不清楚。在一项新的研究中，Guo 及其同事利用先进的小鼠遗传学方法在特定肝区引入致癌驱动突变。结合空间转录组学，他们追踪了组织微环境中的癌前肝细胞。研究者发现，肝门区的第 1 区克隆扩增并长期存在的程度高于肝中央区第 3 区中罕见且相对适应性较差的克隆。然而，矛盾的是，在多种致癌模型中，HCC 主要来源于第 3 区肝细胞，这揭示了克隆扩增能力与肿瘤形成潜能之间显著的不一致。对第 3 区富集转录本的功能筛选发现，谷胱甘肽 S-转移酶 Gstm2 和 Gstm3 在细胞转化中是关键因子。这些酶在早期突变细胞中维持氧化还原平衡并抑制铁死亡。基因缺失、肝细胞特异性敲低以及对 GSTM 的不可逆化学抑制均会增加氧化应激和铁死亡，从而阻止肿瘤形成。将 Gstm3 异位表达于第 1 区即可使这些细胞重新编程，成为肿瘤起始细胞所在区。上述发现界定了肝脏的“致瘤分区”，并提示针对铁死亡脆弱性的治疗可能成为 HCC 的有前景策略。

### 第二部分 AI 大师评价

该研究通过空间转录组学与分区基因编辑探讨了肝癌起源的空间代谢特性。作者发现尽管第 1 区细胞克隆扩张更显著，HCC 却主要起源于第 3 区肝细胞，揭示了克隆活性与致瘤潜力的分离。Gstm2/3 被鉴定为调控铁死亡和维持氧化平衡的关键分子，其抑制可阻断癌变过程。研究创新性地提出“致瘤分区”概念，丰富了对肝癌起源机制的理解。局限性在于该研究主要基于小鼠模型，临床可转化性仍需验证。

---

## 36. 大B细胞淋巴瘤继发中枢神经系统受累的治疗相关结局与复发模式

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490516)
**期刊：** Blood
**PMID：** 41490516
**DOI：** 10.1182/blood.2025031455

### 第一部分 原文与翻译

**英文原标题：** Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

> **英文摘要：**
> Secondary central nervous system (CNS) large B-cell lymphoma (SCNSL) occurs in the de novo setting, as a CNS-isolated relapse, or synchronous (concomitant CNS and systemic) relapse. SCNSL is a devastating event without therapeutic consensus. Thus, we aimed to evaluate treatment outcomes in an international cohort. Progression-free survival (PFS), overall survival (OS) and cumulative incidence of relapse (CIR, estimated using competing-risk models) were reported. Prognostic factors were identified in a 6-month landmark multivariate analysis. Outcomes following thiotepa autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) delivered at relapse were compared following propensity score matching (PSM). A total of 1139 patients were included in the analysis (de novo: 537; relapsed SCNSL: 602). 2-year PFS estimates were 40.4%, 43.9% and 16.2% for de novo SCNSL, CNS-isolated relapse, and synchronous relapse respectively. Patients with CNS-isolated relapse demonstrated low rates of systemic recurrence (24-month CIR 6%). Thiotepa-ASCT correlated with longer survival in de novo SCNSL (PFS: HR=0.57; P=0.005; and OS: HR=0.62; P=0.023) and CNS-isolated relapses (PFS: HR=0.55; P=0.002; and OS: HR=0.39; P<.0001) in 6-month multivariable landmark analysis. ASCT (thiotepa or non-thiotepa) also associated with improved survival in synchronous relapses (PFS: HR=0.57; P=0.023; and OS: HR=0.48; P=0.019). Higher survival with thiotepa-ASCT compared to CAR-T was observed in survival analyses following PSM (PFS: HR=0.45; P=0.005 and OS: HR=0.41; P=0.014). These data support thiotepa-ASCT in eligible patients, particularly de novo disease and CNS-isolated relapses. CNS-isolated relapse was infrequently associated with systemic recurrence, supporting treatment regimens adopted from primary CNS lymphoma.

> **中文摘要：**
> 继发性中枢神经系统（CNS）大B细胞淋巴瘤（SCNSL）可发生于原发（de novo）状态、CNS孤立性复发或同步性（CNS与系统性同时）复发。SCNSL是一种毁灭性的病程事件，目前尚无治疗共识。因此，我们旨在评估一个国际队列中的治疗结果。报道的结局包括无进展生存期（PFS）、总生存期（OS）以及复发的累积发生率（CIR，采用竞争风险模型估计）。在为期6个月的里程碑式多变量分析中确定了预后因素。比较了复发时接受硫替哒自体造血干细胞移植（ASCT）和嵌合抗原受体T细胞治疗（CAR-T）的结局，采用倾向评分匹配（PSM）进行分析。共纳入1139例患者（原发：537例；复发性SCNSL：602例）。2年PFS估计值分别为：原发SCNSL 40.4%、CNS孤立性复发43.9%、同步性复发16.2%。CNS孤立性复发患者表现出较低的系统性复发率（24个月CIR为6%）。在6个月多变量里程碑分析中，硫替哒-ASCT与原发SCNSL的较长生存相关（PFS：HR=0.57，P=0.005；OS：HR=0.62，P=0.023），并在CNS孤立性复发中表现出显著优势（PFS：HR=0.55，P=0.002；OS：HR=0.39，P<0.0001）。ASCT（无论使用硫替哒与否）在同步性复发中同样与改善的生存期相关（PFS：HR=0.57，P=0.023；OS：HR=0.48，P=0.019）。倾向评分匹配后比较显示，硫替哒-ASCT较CAR-T具有更优的生存获益（PFS：HR=0.45，P=0.005；OS：HR=0.41，P=0.014）。这些数据支持在符合条件的患者中应用硫替哒-ASCT，尤其是原发性疾病和CNS孤立性复发者。CNS孤立性复发极少伴随系统性复发，提示可借鉴原发CNS淋巴瘤的治疗方案。

### 第二部分 AI 大师评价

本研究基于国际大规模数据，系统评估了继发性中枢神经系统大B细胞淋巴瘤患者的治疗结局与复发模式。研究结果显示，硫替哒基自体造血干细胞移植在原发及CNS孤立性复发患者中可显著改善生存，与CAR-T疗法相比具有更优优势。研究还指出CNS孤立性复发的系统性复发风险较低，为治疗策略优化提供了重要依据。其创新性在于通过倾向评分匹配和多变量生存分析，再次确认了ASCT在特定亚型中的益处，但仍需前瞻性研究验证以确立最佳治疗路径。

---

## 37. 达沙替尼联合或不联合强化化疗用于核心结合因子急性髓系白血病的Ⅲ期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490515)
**期刊：** Blood
**PMID：** 41490515
**DOI：** 10.1182/blood.2025030722

### 第一部分 原文与翻译

**英文原标题：** Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

> **英文摘要：**
> BACKGROUND: Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT.
> 
> AIMS: We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multi-kinase inhibitor dasatinib in adult patients with CBF-AML.
> 
> METHODS: Patients received "3+7" induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 6-28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg QD. Primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival, relapse-free survival, and cumulative incidence of relapse.
> 
> RESULTS: 202 patients were randomly assigned to the standard arm (n=102) and to the dasatinib arm (n=100). Median age was 49 years (range, 18, 77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); 58 (28.7%) patients had a KIT co-mutation. There was no statistically significant difference in EFS (HR 0.92, 95%-CI 0.63, 1.33; p=0.66) or secondary endpoints between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%).
> 
> CONCLUSION: In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.
> 
> CLINICALTRIALS: gov as NCT02013648.

> **中文摘要：**
> 背景：核心结合因子急性髓系白血病（CBF-AML）与KIT基因突变及KIT表达失调有关。
> 
> 目的：我们报告一项随机、开放标签、Ⅲ期临床试验结果，该试验在成人CBF-AML患者中评估强化化疗联合或不联合多激酶抑制剂达沙替尼的疗效。
> 
> 方法：患者接受“3+7”诱导治疗，随后进行4个周期的大剂量阿糖胞苷巩固治疗；在试验组中，患者于诱导期第8至21天口服达沙替尼100 mg每日一次，在巩固期第6至28天继续服用，之后进行为期12个月的单药达沙替尼（100 mg每日一次）维持治疗。主要终点为无事件生存期（EFS），次要终点包括总生存期（OS）、无复发生存期（RFS）和复发累积发生率。
> 
> 结果：共有202名患者被随机分配至标准组（n=102）和达沙替尼组（n=100）。中位年龄为49岁（范围18–77岁）；其中94名患者具有t(8;21)，108名具有inv(16)/t(16;16)；58名患者（28.7%）伴有KIT共突变。两组间EFS无统计学显著差异（HR 0.92，95% CI 0.63–1.33；p=0.66），次要终点亦无显著差异。按年龄、CBF-AML类型及KIT突变状态分层的亚组分析显示，各亚组间EFS差异均不显著。试验组严重不良事件发生率（64%）高于标准组（36%）。
> 
> 结论：在CBF-AML患者中，将达沙替尼加入强化化疗未能改善生存结局，且伴随毒性增加。本试验注册号为NCT02013648（ClinicalTrials.gov）。

### 第二部分 AI 大师评价

本研究为一项在成人CBF-AML患者中开展的Ⅲ期随机对照试验，旨在评估达沙替尼联合强化化疗的疗效与安全性。结果显示，达沙替尼的加入未能改善事件无生存期、总生存期或复发率，且增加了严重不良事件的发生。研究体现了对多激酶抑制剂在CBF-AML治疗中潜在价值的验证性探索，但结果提示靶向治疗并非所有低风险AML亚型都受益。其局限在于样本量有限及治疗相关毒性的增加。

---

## 38. 勘误：新诊断T淋巴母细胞淋巴瘤的成功疗效——来自儿童肿瘤学组AALL0434研究的结果。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490480)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41490480
**DOI：** 10.1200/JCO-25-02779

### 第一部分 原文与翻译

**英文原标题：** Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为一篇勘误说明，涉及儿童肿瘤学组AALL0434研究中关于新诊断T淋巴母细胞淋巴瘤治疗成果的修正信息。原研究聚焦于儿童或青少年T淋巴母细胞淋巴瘤的治疗结局，并为该罕见疾病提供了系统性临床结果。本勘误旨在更正先前发表数据或结果报告中的细节错误，确保文献数据的准确性与研究结论的可靠性。尽管没有摘要，但通过标题可推测其意义主要在于维护学术与临床数据的完整性。

---

## 39. B细胞非霍奇金淋巴瘤中造血祖细胞的克隆性造血及其与淋巴瘤相关的突变

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490454)
**期刊：** Blood
**PMID：** 41490454
**DOI：** 10.1182/blood.2025030489

### 第一部分 原文与翻译

**英文原标题：** Clonal Hematopoiesis and Lymphoma-Associated Mutations in Hematopoietic Progenitors in B-Cell Non-Hodgkin Lymphoma.

> **英文摘要：**
> Gene-specific expansion patterns were evident among the most frequent CH lesions, with DNMT3A-mutant clones exhibiting impaired hematopoietic differentiation and TET2-mutant clones showing multi-lineage propagation. Notably, identical CH clones were detected in 41% of corresponding lymphomas, displaying distinct clonal dynamics: tumor-promoting CH (expansion in B-NHL; 10/16 clones; mainly TP53) and tumor-infiltrating CH (no expansion; mainly DNMT3A). Moreover, we identified lymphoma-associated mutations in flow-sorted hematopoietic progenitors from patients with indolent but not aggressive B-NHL and observed a stepwise accumulation of mutations along the lymphoid differentiation path. Single-cell genotyping confirmed the presence of mutated progenitors in 3 follicular, 2 mantle cell and 2 marginal zone lymphoma patients, providing direct evidence of a pre-neoplastic state in disease pathogenesis. Our findings offer novel insight into the cellular origin of nodal B-NHLs and highlight a previously underappreciated role for early clonal events involving the stem/progenitor cell compartment.

> **中文摘要：**
> 在最常见的克隆性造血（CH）损伤中，观察到了基因特异性的扩增模式，其中DNMT3A突变克隆表现出造血分化受损，而TET2突变克隆则显示出多谱系扩增。值得注意的是，在41%的相应淋巴瘤中检测到了相同的CH克隆，这些克隆展示出不同的克隆动态：促肿瘤性CH（在B-NHL中扩增；10/16个克隆；主要为TP53）和肿瘤浸润性CH（无扩增；主要为DNMT3A）。此外，我们在惰性型但非侵袭性B-NHL患者的流式分选造血祖细胞中鉴定出了与淋巴瘤相关的突变，并观察到沿淋巴系分化路径的突变逐步累积。单细胞基因分型进一步证实，在3例滤泡性淋巴瘤、2例套细胞淋巴瘤和2例边缘区淋巴瘤患者中存在突变的祖细胞，为疾病发病机制中的癌前状态提供了直接证据。我们的研究结果为结节型B-NHL的细胞起源提供了新的认识，并强调了涉及干/祖细胞区室的早期克隆事件这一此前被低估的作用。

### 第二部分 AI 大师评价

该研究旨在揭示B细胞非霍奇金淋巴瘤（B-NHL）发生过程中克隆性造血与淋巴瘤相关突变之间的关系。作者利用基因突变图谱分析与单细胞分型，发现具有特定基因突变的造血祖细胞可参与肿瘤发生，并揭示不同类型克隆的扩增特征与功能差异。研究首次直接证实了淋巴瘤起源的癌前阶段存在突变祖细胞，为理解B-NHL的细胞演化路径提供了新证据。创新性在于将克隆性造血与淋巴瘤发生机制联系起来，但进一步机制验证和更大样本研究仍是未来方向。

---

## 40. 早期雌激素受体阳性相关乳腺癌的治疗考量

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490448)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41490448
**DOI：** 10.1200/JCO-25-02428

### 第一部分 原文与翻译

**英文原标题：** Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, -Associated Breast Cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供查阅。

### 第二部分 AI 大师评价

该文似为综述性或专家指导类文章，探讨早期雌激素受体阳性乳腺癌的治疗策略与决策依据。文章可能聚焦于内分泌治疗、化疗适应证以及新型辅助治疗的选择标准，为精准医疗提供实践参考。尽管暂无摘要，但可推测其旨在优化早期ER阳性人群的风险分层与个体化治疗方案，具有临床指导意义。

---

## 41. 优化体内CAR-T细胞工程以促进癌症免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490421)
**期刊：** Cancer research
**PMID：** 41490421
**DOI：** 10.1158/0008-5472.CAN-25-3748

### 第一部分 原文与翻译

**英文原标题：** Optimizing In Vivo CAR-T Cell Engineering for Cancer Immunotherapy.

> **英文摘要：**
> Chimeric antigen receptor (CAR)-T cell therapy enables potent, antigen-specific immune responses and has demonstrated success in treating hematologic malignancies. However, conventional ex vivo CAR-T manufacturing remains costly, individualized, and logistically complex, posing significant barriers to accessibility and scalability. In vivo CAR-T cell engineering offers a transformative alternative by reprogramming endogenous T cells within the patient, bypassing the need for cell harvesting and expansion. This review focuses on current in vivo CAR-T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles) and non-viral systems (such as lipid nanoparticles and polymer-based carriers), with a focus on how these platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer. We also discuss the design principles of vector tropism, membrane modifications, and targeting ligands, as well as translational studies in both preclinical and clinical settings. Finally, the review explores delivery-related challenges and future perspectives for optimizing vector stability, enhancing T cell targeting, and reducing immunogenicity to advance in vivo CAR-T therapy toward broader clinical applications.

> **中文摘要：**
> 嵌合抗原受体（CAR）T细胞疗法能够诱导强大且抗原特异性的免疫反应，并已在治疗血液恶性肿瘤中取得成功。然而，传统的体外CAR-T生产依然成本高昂、个体化程度高且物流复杂，构成了可及性与可扩展性的重大障碍。体内CAR-T细胞工程通过在患者体内重新编程内源性T细胞，避免了细胞采集和扩增的需求，从而提供了一种具有变革性的替代方案。本综述聚焦当前体内CAR-T递送策略，包括病毒载体（如慢病毒、γ-逆转录病毒、腺相关病毒和类病毒颗粒）及非病毒系统（如脂质纳米颗粒和聚合物载体），重点探讨这些平台如何被设计以实现高效、特异且安全的CAR转基因传递。我们还讨论了载体嗜性、膜修饰及靶向配体的设计原则，以及在临床前与临床阶段的转化研究。最后，本文探讨了与递送相关的挑战及未来展望，旨在通过优化载体稳定性、增强T细胞靶向性并降低免疫原性，推动体内CAR-T疗法向更广泛的临床应用发展。

### 第二部分 AI 大师评价

本综述系统总结了体内CAR-T工程的最新进展，强调通过体内递送技术实现T细胞的原位重编程，为克服传统CAR-T生产的成本与复杂性提供了新路径。作者综合分析了病毒与非病毒载体的工程化策略及其在效率、安全性和特异性方面的优化思路。文章还讨论了载体嗜性、膜修饰与靶向配体等关键设计原理，并结合临床前与临床研究阐述了转化潜力。总体而言，该研究具有较强的创新性，但体内安全性与免疫原性仍是未来需要突破的关键瓶颈。

---

## 42. 骨髓衰竭、通过 p53 失活的体细胞补偿以及种系 ERCC6L2 疾病中增强的白血病发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490322)
**期刊：** Blood
**PMID：** 41490322
**DOI：** 10.1182/blood.2025030230

### 第一部分 原文与翻译

**英文原标题：** Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germline ERCC6L2 disease.

> **英文摘要：**
> Recessively inherited loss-of-function mutations in Excision Repair Cross-Complementing 6 like 2 (ERCC6L2) cause a bone marrow failure (BMF) syndrome characterized by moderate cytopenias, frequent somatic TP53 mutations, and a propensity to develop myeloid malignancies. The pathophysiology and molecular mechanisms underlying the BMF syndrome as well as its association with TP53-mutant clonal hematopoiesis (CH) and myeloid malignancies have remained poorly understood. Using novel preclinical in vitro and in vivo model systems, we demonstrate that Ercc6l2 maintains the competitive ﬁtness of hematopoietic stem and progenitor cells (HSPCs) by mitigating replication stress. Sustained replication stress and DNA damage in Ercc6l2-deficient HSPCs cause p53 pathway activation followed by cell cycle arrest and apoptosis. Moreover, Ercc6l2 deficiency results in decreased expression of master hematopoietic regulators Runx1 and Gata1 in HSPCs. Altogether, loss of Ercc6l2 leads to reduced HSPC numbers, bone marrow hypocellularity, and cytopenias. Notably, somatic Trp53 mutations restore cellular fitness of Ercc6l2-deficient HSPCs by abrogating p53 pathway activation and restoring Runx1 and Gata1 expression, thereby correcting the BMF phenotype. However, p53 loss fails to normalize replication stress, allowing for the accumulation of DNA damage over time which increases the likelihood for leukemic transformation. Our data uncover the pathogenesis of ERCC6L2 disease and provide a prototypic example of clonal compensation in BMF syndromes, where somatic mutations in leukemia-associated genes - in this case TP53 - transiently improve blood cell production at, however, the expense of increasing leukemogenic potential.

> **中文摘要：**
> 隐性遗传的 Excision Repair Cross-Complementing 6 like 2（ERCC6L2）功能缺失突变会导致一种骨髓衰竭（BMF）综合征，其特征为中度细胞减少、频繁的体细胞 TP53 突变以及发生髓系恶性肿瘤的倾向。该骨髓衰竭综合征的病理生理和分子机制，以及其与 TP53 突变克隆性造血（CH）和髓系恶性肿瘤之间的关系，迄今仍不清楚。利用新的临床前体外和体内模型系统，我们证明 Ercc6l2 通过缓解复制应激来维持造血干/祖细胞（HSPCs）的竞争性适应性。在 Ercc6l2 缺陷的 HSPCs 中，持续的复制应激和 DNA 损伤会引发 p53 通路激活，继而导致细胞周期停滞和凋亡。此外，Ercc6l2 缺陷还会导致 HSPCs 中造血主调控因子 Runx1 和 Gata1 的表达下降。总体而言，Ercc6l2 的缺失导致 HSPC 数量减少、骨髓细胞减少及外周血细胞减少。值得注意的是，体细胞 Trp53 突变可通过抑制 p53 通路激活并恢复 Runx1 与 Gata1 表达，从而恢复 Ercc6l2 缺陷 HSPCs 的细胞适应性并纠正 BMF 表型。然而，p53 的缺失未能纠正复制应激，因而随时间积累的 DNA 损伤增加了白血病转化的可能性。我们的研究揭示了 ERCC6L2 疾病的发病机制，并提供了骨髓衰竭综合征中克隆性补偿的原型实例——在该情况下，与白血病相关的基因（此处为 TP53）体细胞突变虽可短暂改善造血，但代价是白血病潜能的增强。

### 第二部分 AI 大师评价

本研究揭示了 ERCC6L2 缺陷导致骨髓衰竭的分子机制，并通过体外及体内模型阐明了其与 p53 通路和克隆性造血之间的联系。研究发现，Ercc6l2 缺陷引起的复制应激触发 p53 激活，导致造血干/祖细胞耗竭，而体细胞 TP53 突变可暂时缓解这一表型。该工作创新性地提出“克隆性补偿”概念，展示了体细胞突变如何在短期内恢复造血、但同时提升白血病风险。局限性在于模型系统能否完全模拟人类病理过程仍需进一步验证。

---

## 43. 利用 CD2 轴扩展并增强 CAR T 细胞疗法的疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490267)
**期刊：** Blood
**PMID：** 41490267
**DOI：** 10.1182/blood.2025031409

### 第一部分 原文与翻译

**英文原标题：** Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.

> **英文摘要：**
> Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells against T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective anti-tumor responses while preventing CAR T-cell fratricide. We hypothesized that targeting CD2, a pan-T-cell antigen, using anti-CD2 CAR T-cells engineered without CD2 expression (CART2), would support CAR T-cell manufacturability and preclinical efficacy. Optimized CD2-knockout CART2, generated using CRISPR-Cas9, eradicated primary patient-derived CD2+ hematological neoplasms in vitro and in vivo, secreted effector cytokines, and exhibited adequate proliferative capacity. Nevertheless, CD2 has a key costimulatory function, and its deletion could lead to CAR T-cell dysfunction. Therefore, we tested the role of the CD2:CD58 axis in CAR T-cells, using the anti-CD19 CART models. We demonstrate that CD2 loss attenuates CART19 efficacy by reducing avidity for tumor antigen, co-stimulation, and ultimately in vivo activity. Analogously, we show that tumor CD58 loss reduces CART19 efficacy. To overcome this issue, we developed a novel PD-1:CD2 switch receptor that rescues intracellular CD2 signaling, particularly when PD-L1 is engaged, resulting in improved in vivo outcomes. Collectively, we studied the role of CD2 both as a target for CAR T cell therapy and as a critical costimulatory protein, whose signaling can be rescued using the PD-1:CD2 switch receptor. This receptor can be incorporated into CAR T-cells and provides an effective strategy to overcome CD2-signaling deficiencies.

> **中文摘要：**
> 由于缺乏具有靶向性和有效性的治疗手段，特别是在复发和难治情况下，T 细胞淋巴瘤和白血病患者的整体预后较差。针对 T 细胞肿瘤开发嵌合抗原受体（CAR）T 细胞的进展受到限制，原因是缺乏能够在防止 CAR T 细胞自相残杀的同时诱导有效抗肿瘤反应的差异性 T 细胞抗原。我们假设，靶向 CD2（一种泛 T 细胞抗原），并利用去除 CD2 表达的抗 CD2 CAR T 细胞（CART2），可支持 CAR T 细胞的可制造性和临床前疗效。采用 CRISPR-Cas9 技术制备的优化型 CD2 敲除 CART2，可在体内外根除来源于患者的 CD2+ 血液系统肿瘤，分泌效应性细胞因子，并表现出良好的增殖能力。然而，CD2 具有关键的共刺激功能，其缺失可能导致 CAR T 细胞功能障碍。因此，我们利用抗 CD19 CAR T 模型研究 CD2:CD58 轴在 CAR T 细胞中的作用。我们证明，CD2 的缺失通过降低 CAR T19 对肿瘤抗原的亲和力和共刺激能力，从而削弱了其体内活性。同样，我们发现肿瘤细胞缺失 CD58 也会降低 CAR T19 的疗效。为克服这一问题，我们开发了新型 PD-1:CD2 开关受体，可在 PD-L1 介导作用时恢复细胞内 CD2 信号传导，从而改善体内疗效。综上所述，我们研究了 CD2 既作为 CAR T 细胞治疗靶点，又作为关键共刺激蛋白的作用，其信号可通过 PD-1:CD2 开关受体得以恢复。该受体可被整合入 CAR T 细胞中，为克服 CD2 信号缺陷提供了一种有效策略。

### 第二部分 AI 大师评价

本研究旨在探索 CD2 轴在 CAR T 细胞疗法中的双重作用，即作为治疗靶标和关键共刺激通路。作者通过 CRISPR-Cas9 技术构建 CD2 敲除型抗 CD2 CAR T 细胞，证实其对 CD2 阳性血液恶性肿瘤具有良好的杀伤活性。进一步研究显示，CD2 或其配体 CD58 的缺失会削弱 CAR T 细胞功能。研究团队创新性地设计了 PD-1:CD2 开关受体，以恢复 CD2 信号传导并改善体内抗肿瘤活性。该工作为优化 CAR T 细胞效能、克服信号缺陷提供了新的分子工程策略。

---

## 44. 用于癌症治疗的G1/S转变抑制新兴策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41490149)
**期刊：** Cancer research
**PMID：** 41490149
**DOI：** 10.1158/0008-5472.CAN-25-0916

### 第一部分 原文与翻译

**英文原标题：** Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.

> **英文摘要：**
> At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic studies have identified the key molecular regulators of the transition from G1 to S phase in the cell cycle that commits cells to division. During the G1/S transition, the cyclin-dependent kinases CDK4 and CDK6 (CDK4/6) form complexes with cyclin D that phosphorylate and inhibit the retinoblastoma protein (RB). The resulting activation of E2F transcription factors then drives progression into S phase. The centrality of the G1/S transition for proliferation motivated the development of small molecule ATP-competitive CDK4/6 inhibitors, which block the first step of this pathway and are now standard of care for some forms of breast cancer. While successful, these therapeutics have limitations that have motivated the development of alternative approaches to targeting CDKs and the cell cycle. Here, we review how recently developed inhibitors of CDKs and other components of the G1/S pathway may be used, as single agents or in combination therapies, to oppose the growth of human cancers.

> **中文摘要：**
> 从根本上说，癌症是一种由受扰分子通路介导的细胞增殖失控疾病，这些通路在过去的几十年中已被阐明。生化和遗传学研究已鉴定出细胞周期中从G1期到S期转变这一决定细胞进入分裂的关键分子调控因子。在G1/S转变过程中，细胞周期依赖性激酶CDK4和CDK6（统称CDK4/6）与细胞周期蛋白D形成复合物，进而磷酸化并抑制视网膜母细胞瘤蛋白（RB）。随后的E2F转录因子的激活推动细胞周期进入S期。G1/S转变在细胞增殖中的核心地位促使人们开发了小分子ATP竞争性CDK4/6抑制剂，这类药物阻断该通路的首个步骤，现已成为某些类型乳腺癌的标准治疗方法。尽管这些治疗取得了成功，但其局限性也促使人们探索以CDK及细胞周期为靶点的替代策略。在本文中，我们综述了最近开发的CDK抑制剂及G1/S通路其他组分抑制剂如何作为单药或联合疗法应用于抑制人类癌症的生长。

### 第二部分 AI 大师评价

本文综述性地探讨了在癌症治疗中靶向G1/S转变的最新策略。其核心目的是总结抑制细胞周期关键节点—CDK4/6及相关分子—的新方法，包括新型抑制剂与组合疗法的潜力。文章全面阐述了该通路在细胞增殖控制中的生物学重要性，并指出现有CDK4/6抑制剂的疗效与局限。创新性在于强调从单一ATP竞争性抑制向更广泛、多靶点干预策略的转变，但仍需更多临床证据来验证这些新方案的效果与安全性。

---

## 45. 靶向前列腺癌中的雄激素受体通路：一场漫长的斗争

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41160408)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41160408
**DOI：** 10.1158/1078-0432.CCR-25-3045

### 第一部分 原文与翻译

**英文原标题：** Targeting the Androgen Receptor Pathway in Prostate Cancer: A PROTrACted Struggle.

> **英文摘要：**
> The androgen receptor (AR) is the most important therapeutic target for metastatic prostate cancer. Though clinical responses to AR inhibition are nearly universal, so is progression, usually accompanied by reactivation of AR signaling. A new small-molecule dual AR degrader/inhibitor shows promise in overcoming resistance and improving clinical outcomes. See related article by Nayak et al., p. 224.

> **中文摘要：**
> 雄激素受体（AR）是转移性前列腺癌中最重要的治疗靶点。虽然AR抑制治疗几乎普遍可获得临床应答，但疾病进展也同样普遍发生，通常伴随AR信号的再激活。一种新型小分子双重作用的AR降解剂/抑制剂在克服耐药性和改善临床结局方面显示出前景。参见Nayak等人的相关文章，第224页。

### 第二部分 AI 大师评价

本研究聚焦于前列腺癌中雄激素受体通路这一核心靶点，强调了AR信号在耐药与疾病进展中的关键作用。摘要介绍了一种新型小分子药物，既能降解又能抑制AR，为克服既往AR抑制剂导致的耐药提供了新策略。该研究体现了前列腺癌治疗从功能阻断走向靶向降解的转变思路，具有潜在临床创新价值。但其疗效与安全性仍需进一步通过临床研究验证。

---

## 46. RANKL抗体地舒单抗在两组复发/难治性骨肉瘤患者中的II期临床试验——来自儿童肿瘤学组的报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159913)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41159913
**DOI：** 10.1158/1078-0432.CCR-24-2885

### 第一部分 原文与翻译

**英文原标题：** A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.

> **英文摘要：**
> PURPOSE: Mouse models demonstrate a role for RANK and its ligand, RANKL, in osteosarcoma. The primary objective of this single-arm, open-label phase 2 trial was to determine whether denosumab, a RANKL mAb, improved disease control in recurrent osteosarcoma relative to benchmarks derived from historic Children's Oncology Group clinical trial data.
> 
> PATIENTS AND METHODS: Skeletally mature patients ages 11 to 49 years old with measurable disease were eligible for cohort 1, and those with complete surgical resection of all sites of disease were eligible for cohort 2. Patients received denosumab 120 mg subcutaneously every 4 weeks with calcium and vitamin D supplementation. The primary endpoints were RECIST response and remaining event-free for 4 months for cohort 1 and remaining event-free for 12 months for cohort 2. Toxicity, pharmacokinetics, and pharmacodynamic effects were additional endpoints.
> 
> RESULTS: Fifteen patients in cohort 1 and 38 in cohort 2 were eligible and evaluable for the primary endpoint. One of 15 cohort 1 patients remained event-free at 4 months. There were no objective responses. Ten of 38 cohort 2 patients were event-free at 12 months. The predefined efficacy criteria were not met in either cohort. The most common ≥ grade 3 adverse events were hypocalcemia and hypophosphatemia (8% and 11%, respectively). At steady state, mean serum denosumab trough concentrations were 23.7 to 31 μg/mL in cycles 2 to 7. Serum c-telopeptide and urine n-telopeptide decreased on treatment.
> 
> CONCLUSIONS: Denosumab was well-tolerated with anticipated side effects and pharmacokinetic and pharmacodynamic parameters but had insufficient activity for further development in osteosarcoma.

> **中文摘要：**
> 研究目的：小鼠模型显示，RANK及其配体RANKL在骨肉瘤的发生中起作用。本单臂、开放标签的II期临床试验的主要目的，是确定RANKL单克隆抗体地舒单抗（denosumab）是否能相较于儿童肿瘤学组以往临床试验数据的基准，改善复发性骨肉瘤的疾病控制。
> 
> 患者与方法：年龄在11至49岁且骨骼发育成熟并具有可测量病灶的患者被纳入第1队列；所有病灶已完全外科切除的患者被纳入第2队列。患者每4周皮下注射地舒单抗120 mg，并补充钙和维生素D。主要终点为：第1队列的RECIST反应及4个月无事件生存率，第2队列的12个月无事件生存率。毒性、不良反应、药代动力学和药效学效应为附加终点。
> 
> 结果：第1队列中15例、第2队列中38例患者符合入组并可评估主要终点。第1队列中仅1例患者在4个月时无事件发生，未观察到客观缓解。第2队列中有10例患者在12个月时无事件发生。两个队列均未达到预设疗效标准。最常见的≥3级不良事件为低钙血症和低磷血症，发生率分别为8%和11%。在稳态时，地舒单抗血清谷浓度在第2至第7周期间的平均值为23.7至31 μg/mL。治疗过程中，血清C端交联肽及尿液N端交联肽水平下降。
> 
> 结论：地舒单抗耐受性良好，具有预期的副作用及药代、药效学特征，但其在骨肉瘤中的活性不足，暂不支持进一步开发。

### 第二部分 AI 大师评价

本研究旨在评估RANKL单抗地舒单抗对复发或难治性骨肉瘤的疗效。研究采用单臂开放的II期设计，分别观察存在残余病灶与完全切除病灶患者的无事件生存率。结果显示，尽管药物安全性良好，并呈现预期的生物学活性变化，但未能达到预设疗效标准。该研究验证了RANKL通路在骨肉瘤中的潜在作用，但也揭示了地舒单抗单药治疗的局限性，为未来针对该通路的联合或分层治疗策略提供了依据。

---

## 47. plasmaMATCH 试验中晚期乳腺癌患者 ctDNA 水平的预后与预测价值研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159912)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41159912
**DOI：** 10.1158/1078-0432.CCR-24-0651

### 第一部分 原文与翻译

**英文原标题：** The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.

> **英文摘要：**
> PURPOSE: ctDNA dynamic levels may identify patients who will respond to therapy. We assessed ctDNA baseline levels and on-treatment dynamics in patients with advanced breast cancer on the plasmaMATCH trial with mutation-targeted therapies (cohorts A-D) and triple-negative breast cancer on olaparib and ceralasertib combination (cohort E).
> 
> EXPERIMENTAL DESIGN: Blood samples were collected at baseline [cycle 1 day 1 (C1D1)] and before treatment on cycle 2 day 1 (C2D1). Samples were sequenced using error-corrected targeted panels (Guardant360/GuardantOMNI). Circulating DNA ratio was calculated as the ratio of C2D1/C1D1 circulating DNA ratio, and baseline ctDNA levels were associated with progression-free survival (PFS) and confirmed objective response rates (ORR).
> 
> RESULTS: A total of 167 patients had assessable C1D1-C2D1 ctDNA results. There was a strong association between baseline ctDNA levels and response in cohort E; low baseline levels were associated with longer PFS (HR, 0.33; P = 0.001) and higher ORR (40% vs. 9.7%; P = 0.02). In cohorts A to D, there was a weaker association with PFS (HR, 0.60; P = 0.03) and ORR (15.2% vs. 5.7%; P = 0.17). Associations of baseline ctDNA level and ORR were validated in the independent PEARL study. For on-treatment dynamics, suppression of ctDNA below median was predictive in cohorts A to D (HR, 0.47; P = 0.001) but not in cohort E (HR, 1.02; P = 0.94). Undetectable ctDNA levels at C2D1 were associated with good outcomes in both cohorts: in cohort E with improved PFS (HR, 0.25; P = 0.01) and improved ORR (86% vs. 11%; P = 0.01). Six of seven patients with undetectable on-treatment ctDNA were BRCA1/BRCA2/PALB2 wild type.
> 
> CONCLUSIONS: Baseline low ctDNA levels predict response to targeted therapy, potentially suggesting shared mechanisms between high ctDNA release and resistance to therapy. Both baseline ctDNA levels and on-treatment dynamics are a promising surrogate endpoint for drug development, with clearance of ctDNA being a robust cross-therapy surrogate for outcomes.

> **中文摘要：**
> 目的：ctDNA 的动态水平可能有助于识别对治疗有反应的患者。我们在 plasmaMATCH 试验中评估了晚期乳腺癌患者的 ctDNA 基线水平及治疗期间的动态变化，其中突变靶向治疗对应 A–D 队列，奥拉帕利与 ceralasertib 联合治疗的三阴性乳腺癌对应 E 队列。
> 
> 实验设计：在基线［第 1 周期第 1 天（C1D1）］及第 2 周期第 1 天（C2D1）治疗前采集血样。样本经纠错的靶向测序面板（Guardant360/GuardantOMNI）测定。循环 DNA 比值计算为 C2D1/C1D1 的循环 DNA 比值，基线 ctDNA 水平与无进展生存期（PFS）及确认的客观缓解率（ORR）进行关联分析。
> 
> 结果：共有 167 例患者获得可评估的 C1D1–C2D1 ctDNA 结果。在 E 队列中，基线 ctDNA 水平与治疗反应呈显著相关；低基线水平患者具有更长的 PFS（危险比 HR = 0.33；P = 0.001）及更高的 ORR（40% 对 9.7%；P = 0.02）。在 A–D 队列中，PFS 的相关性较弱（HR = 0.60；P = 0.03），ORR 差异亦不显著（15.2% 对 5.7%；P = 0.17）。基线 ctDNA 水平与 ORR 的关联在独立的 PEARL 研究中得到验证。关于治疗期间的动态变化，A–D 队列中 ctDNA 降至中位数以下具有预测价值（HR = 0.47；P = 0.001），但 E 队列中未见此现象（HR = 1.02；P = 0.94）。在 C2D1 时 ctDNA 不可检出的患者在两类队列中均表现出较好结局：E 队列中表现为 PFS 改善（HR = 0.25；P = 0.01）及较高 ORR（86% 对 11%；P = 0.01）。7 例治疗期间 ctDNA 不可检出患者中有 6 例为 BRCA1/BRCA2/PALB2 野生型。
> 
> 结论：基线低 ctDNA 水平可预测靶向治疗反应，提示高 ctDNA 释放与治疗耐药可能存在共同机制。基线 ctDNA 水平及治疗期间动态变化均可能成为药物研发中有前景的替代终点，其中 ctDNA 清除是跨疗法结果的稳健替代指标。

### 第二部分 AI 大师评价

本研究系统评估了 plasmaMATCH 试验中 ctDNA 基线水平及动态变化对晚期乳腺癌预后与疗效预测的价值。结果显示，低基线 ctDNA 与更佳的无进展生存和客观缓解率显著相关，ctDNA 的清除亦能反映良好的治疗效果。该研究通过跨队列与独立验证强化了 ctDNA 作为替代终点的潜力，为精准治疗监测提供了重要证据。然而，需要进一步在更大样本及不同疗法中确认其通用性。

---

## 48. 迈向ROME之路：定义精准肿瘤学中组织与液体一致性的概念

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41148201)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41148201
**DOI：** 10.1158/1078-0432.CCR-25-3143

### 第一部分 原文与翻译

**英文原标题：** On the Road to ROME: Defining Tissue-Liquid Concordance in Precision Oncology.

> **英文摘要：**
> A growing body of evidence has established liquid biopsy as a promising, noninvasive platform for genomic profiling. In this commentary, we build on findings from the multicenter, randomized phase II ROME trial and interrogate the challenges and opportunities of tissue-liquid profiling concordance in improving personalized cancer treatment and survival outcomes. See related article by Botticelli et al., p. 45.

> **中文摘要：**
> 越来越多的证据表明，液体活检已成为一种前景广阔的、无创的基因组分析平台。在本评论中，我们基于多中心、随机的Ⅱ期ROME试验的研究结果，探讨了组织—液体分析一致性在改善个体化癌症治疗和生存结局中的挑战与机遇。参见Botticelli等的相关文章，第45页。

### 第二部分 AI 大师评价

本文基于多中心Ⅱ期ROME试验的最新成果，聚焦于液体活检与组织检测之间的一致性问题，旨在优化精准肿瘤学中的基因组分析策略。作者在评述中揭示了两种检测方法在个体化治疗指导和预后评估中的潜力与局限。该文的创新在于系统化地强调了组织与液体取样间的互补关系，为未来精准治疗的标准化提供了理论依据。但作为评论性研究，其仍需进一步的实证数据支持以验证所提假设。

---

## 49. PI3Kα抑制剂及降解剂Inavolisib可协同FGFR2，在PIK3CA突变型实体瘤患者及临床前模型中增强治疗反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41143603)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41143603
**DOI：** 10.1158/1078-0432.CCR-25-1459

### 第一部分 原文与翻译

**英文原标题：** PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

> **英文摘要：**
> PURPOSE: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor-positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally shown modest single-agent activity and have safety concerns.
> 
> PATIENTS AND METHODS: A first-in-human phase 1 study (NCT03006172) evaluated oral inavolisib in patients with PIK3CA-mutated solid tumors to determine the maximum tolerated dose and safety. Correlative analyses included ctDNA. Preclinical studies in cell lines and xenografts elucidated the role of FGFR2.
> 
> RESULTS: The maximum tolerated dose was 9 mg daily, with a manageable safety profile (e.g., hyperglycemia and diarrhea). Inavolisib showed linear pharmacokinetics, consistent pharmacodynamic modulation, and antitumor activity in hormone receptor-positive PIK3CA-mutated breast cancer (26% objective response rate and 45% clinical benefit rate). FGFR2 hotspot mutations in ctDNA were strongly associated with clinical benefit. Preclinically, oncogenic FGFR2 signaling enhanced inavolisib sensitivity by engaging HER3, RAS, and p85β, that facilitated mutated p110α degradation, surpassing nondegrading inhibitors. Combination therapy with FGFR2 inhibitors showed synergy and delayed resistance.
> 
> CONCLUSIONS: These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/FGFR2-altered tumors.

> **中文摘要：**
> 研究目的：PIK3CA突变常见于多种实体瘤中，尤其是激素受体阳性的乳腺癌。Inavolisib是一种ATP竞争性p110α抑制剂，同时能够促进突变型p110α的降解。PI3K抑制剂整体上作为单药的活性有限，并伴有安全性问题。
> 
> 患者与方法：这项首次人体I期研究（NCT03006172）评估了口服Inavolisib在PIK3CA突变型实体瘤患者中的最大耐受剂量及安全性。相关性分析包括ctDNA检测。临床前研究在细胞系和异种移植模型中阐明了FGFR2的作用。
> 
> 结果：最大耐受剂量为每日9毫克，安全性可控（如高血糖和腹泻）。Inavolisib表现出线性药代动力学特征、一致的药效学调节作用，并在激素受体阳性、PIK3CA突变型乳腺癌中具有抗肿瘤活性（客观缓解率26%，临床获益率45%）。ctDNA中的FGFR2热点突变与临床获益高度相关。在临床前研究中，致癌性FGFR2信号通过介导HER3、RAS和p85β的参与，增强了Inavolisib的敏感性，并促进突变型p110α的降解，其效果优于不具降解活性的抑制剂。与FGFR2抑制剂的联合治疗显示出协同效应并可延缓耐药。
> 
> 研究结论：这些结果揭示了FGFR2与p110α之间新的协同机制，从而提高了Inavolisib的疗效。该研究支持将精准肿瘤治疗从单一生物标志物拓展至利用共存改变的复杂算法，提示Inavolisib联合FGFR2抑制剂可能在PIK3CA/FGFR2改变的肿瘤中获得更强且更持久的疗效。

### 第二部分 AI 大师评价

本研究通过首次人体试验和临床前研究，系统评估了PI3Kα抑制剂及降解剂Inavolisib在PIK3CA突变实体瘤中的应用价值。研究发现FGFR2信号通路可增强Inavolisib的抗肿瘤效应，并揭示其通过促进突变型p110α降解的分子机制。临床数据展示了可控的安全性和有意义的疗效，尤其在FGFR2共突变者中更显著。其创新点在于发现FGFR2与PI3Kα的协同作用机制，为精准肿瘤治疗提供了新的联合策略；但研究仍需在更大样本和长期随访中进一步验证疗效与耐药机制。

---

## 50. 肿瘤起源细胞亚型预测大B细胞淋巴瘤对Polatuzumab Vedotin的治疗反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41143601)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41143601
**DOI：** 10.1158/1078-0432.CCR-25-2392

### 第一部分 原文与翻译

**英文原标题：** Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

> **英文摘要：**
> PURPOSE: Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial. However, when stratified by cell of origin (COO), polatuzumab seems to have greater efficacy in activated B-cell than germinal center B-cell (GCB) subtype disease. Most studies of polatuzumab used RNA expression to assess COO, whereas in routine clinical practice, the immunohistochemistry-based Hans algorithm is used.
> 
> EXPERIMENTAL DESIGN: To assess the impact of COO by immunohistochemistry on polatuzumab efficacy, we conducted a multicenter real-world study of adults with large B-cell lymphoma (LBCL) receiving polatuzumab from 2015 to 2024, split by receipt of polatuzumab in first-line versus relapsed/refractory settings. The primary endpoint was overall response rate (ORR) to polatuzumab-based treatment in GCB versus non-GCB relapsed/refractory LBCL.
> 
> RESULTS: Of 740 patients, 305 received polatuzumab in the first-line setting and 435 in the relapsed/refractory setting. In the relapsed/refractory cohort, the ORR in non-GCB versus GCB LBCL was 59.7% versus 36.3% [OR, 2.6; 95% confidence interval (CI), 1.77-3.84; P < 0.0001], with a complete response rate of 35.7% versus 17.7% (OR, 2.6; 95% CI, 1.66-4.02; P < 0.0001). Progression-free survival was longer for patients with non-GCB versus GCB COO (HR, 0.64; 95% CI, 0.5-0.83; P = 0.0006). In the first-line cohort, ORR, complete response rate, and progression-free survival were similar in non-GCB versus GCB LBCL, as hypothesized based on outcomes in the Pola-R-CHP arm of POLARIX, suggesting that the addition of polatuzumab overcomes the adverse risk of non-GCB COO in patients receiving R-CHOP.
> 
> CONCLUSIONS: Based on these data, COO classification by the Hans algorithm is a strong predictor of polatuzumab efficacy in LBCL, informing real-world treatment decisions.

> **中文摘要：**
> 研究目的：基于POLARIX试验结果，Polatuzumab vedotin（简称polatuzumab）获批联合化疗免疫方案（Pola-R-CHP）用于弥漫性大B细胞淋巴瘤的一线治疗。然而，当按照肿瘤起源细胞（COO）进行分型时，polatuzumab在活化型B细胞（ABC）亚型中的疗效优于生发中心B细胞（GCB）亚型。多数针对polatuzumab的研究采用RNA表达评估COO，而常规临床实践中则多使用基于免疫组化的Hans算法。
> 
> 实验设计：为评估免疫组化法定义的COO对polatuzumab疗效的影响，我们开展了一项多中心真实世界研究，纳入2015至2024年间接受polatuzumab治疗的成人大B细胞淋巴瘤（LBCL）患者。研究根据患者接受polatuzumab的一线治疗或复发/难治（R/R）治疗进行分组。主要终点为R/R LBCL中GCB与非GCB亚型患者接受polatuzumab治疗的总体缓解率（ORR）。
> 
> 研究结果：在740例患者中，305例接受一线polatuzumab治疗，435例接受R/R治疗。在R/R队列中，非GCB与GCB亚型的ORR分别为59.7%与36.3%［比值比（OR）=2.6；95%置信区间（CI）：1.77-3.84；P<0.0001］，完全缓解率分别为35.7%与17.7%（OR=2.6；95% CI：1.66-4.02；P<0.0001）。非GCB亚型患者的无进展生存期较GCB亚型更长（风险比HR=0.64；95% CI：0.5-0.83；P=0.0006）。在一线治疗队列中，非GCB与GCB亚型的ORR、完全缓解率及无进展生存期相似，与POLARIX试验中Pola-R-CHP组的结果一致，提示在R-CHOP方案中加入polatuzumab可克服非GCB亚型的不良预后风险。
> 
> 研究结论：基于本研究数据，Hans算法定义的COO分型是预测LBCL患者接受polatuzumab疗效的强有力指标，可为临床实践中的治疗决策提供支持。

### 第二部分 AI 大师评价

该研究旨在探讨起源细胞亚型（COO）对Polatuzumab Vedotin疗效的预测作用，采用免疫组化Hans算法分型方法，并在多中心真实世界人群中验证。结果显示，在复发/难治LBCL患者中，非GCB亚型对Polatuzumab的疗效显著优于GCB亚型，而在一线治疗中两者疗效相当。这一发现强化了COO在靶向治疗决策中的指导价值，并提示Polatuzumab可部分克服非GCB亚型的不良预后。研究的创新性在于将免疫组化分型与实际临床疗效关联，但作为回顾性真实世界研究，仍需前瞻性试验进一步验证。

---

## 51. 不良组织学与临床分期M的顺序组合界定高危神经母细胞瘤：儿童肿瘤学组的研究报告

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41143597)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41143597
**DOI：** 10.1158/1078-0432.CCR-24-4369

### 第一部分 原文与翻译

**英文原标题：** Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.

> **英文摘要：**
> PURPOSE: Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).
> 
> EXPERIMENTAL DESIGN: The cohort of patients with neuroblastoma previously used for developing the Children's Oncology Group-Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.
> 
> RESULTS: This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I-IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.
> 
> CONCLUSIONS: The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.

> **中文摘要：**
> 研究目的：在历史上，神经母细胞瘤的风险分层通常以临床分期为起点，然后依次加入其他预后因素。本研究采用一种替代方法，从国际神经母细胞瘤病理分类（INPC）入手，来定义神经母细胞瘤患者的风险分组。
> 
> 实验设计：研究重新分析了此前用于建立儿童肿瘤学组修订版神经母细胞瘤风险分类（RNRC）系统的神经母细胞瘤患者队列，采用生存树回归分析方法，以INPC区分有利组织学和不良组织学两类为起点。所得两条分支首先根据国际神经母细胞瘤风险组分期系统进行细分，并依次加入其他预后因素。
> 
> 研究结果：新的分层系统——INPC风险分组（INPC-RG）比RNRC系统更为简洁，去除了不必要的决策树，区分出四个风险组（I–IV组）。仅使用INPC（不良组织学）和国际神经母细胞瘤风险组分期系统（M期），INPC-RG即可定义出侵袭性极高的IV组肿瘤患者，其5年无事件生存率低于RNRC高危组。此外，该系统还能识别出III组患者，其5年无事件生存率介于50%至80%，而RNRC系统并未能识别此类人群。
> 
> 研究结论：采用新的INPC-RG系统具有四个主要优势：（1）可快速识别IV组患者；（2）为进一步细化III组奠定基础；（3）在肿瘤组织取材有限的情况下亦可实现患者分层；（4）使资源有限地区的患者亦能得到合理分层，从而有望改善全球范围内神经母细胞瘤患者的治疗效果。

### 第二部分 AI 大师评价

本研究基于INPC重新定义了神经母细胞瘤的风险分层框架，提出了较RNRC更为简洁的INPC-RG系统。研究利用生存树回归分析验证，仅凭组织学类型及分期即可有效区分不同预后群体。结果显示，该系统不仅能更精确识别极高危患者，还能发现中间风险层的新亚群。其创新之处在于以病理分类为起点，提升了可操作性与推广潜力，但仍需前瞻性验证其在多中心与不同资源条件下的适用性。

---

速递结束，祝您工作愉快！